Consolidated Financial Statements

With Independent Auditors' Report For the Six Months Ended June 30, 2023 and 2022

Address: No. 29 Jianguo E. Rd., Guishan, Dist., Taoyuan City 333403, Taiwan (R.O.C.) Telephone: 886-3-374-8800

The independent auditors' report and the accompanying consolidated financial statements are the English translation of the Chinese version prepared and used in the Republic of China. NOT AUDITED OR REVIEWED BY AUDITORS. If there is any conflict between, or any difference in the interpretation of the English and Chinese language independent auditors' report and consolidated financial statements, the Chinese version shall prevail.

Table of contents

Contents	Page
Cover Page	I
Table of Contents	2
Independent Auditors' Report	3
Consolidated Balance Sheets	4-5
Consolidated Statements of Comprehensive Income	6
Consolidated Statements of Changes in Equity	7
Consolidated Statements of Cash Flow	8~9
Notes to the Consolidated Financial Statements	
I. Organization and business	10
2. Approval of financial statements	10
3. Application of New and Revised Accounting Standards and Interpretations	10-11
4. Summary of significant accounting policies	~ 2
Critical accounting judgments and key sources of estimation and assumption uncertainty	12
6. Description of Significant Accounts	12~42
7. Related-party transactions	42~46
8. Pledged assets	46
9. Significant commitments and contingencies	46
10. Significant loss from disaster	46
II. Significant subsequent events	46
12. Others	46~47
13. Additional disclosures	
(1) Information of significant transactions	48~51
(2) Information of investees	51-52
(3) Information of investments in Mainland China	52
(4) Major shareholders information	52
14. Segment information	53~54

Independent Auditors' Report

To the Board of Directors of BenQ Materials Corporation:

Introduction

We have reviewed the accompanying consolidated balance sheets of BenQ Materials Corporation and its subsidiaries as of June 30, 2023 and 2022, the related consolidated statements of comprehensive income, for the three months ended June 30, 2023 and 2022, and for the six months ended June 30, 2023 and 2022, the consolidated statements of changes in equity and cash flows then ended, and the related notes to the consolidated financial statements, including a summary of significant accounting policies. Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and International Accounting Standard ("IASs") 34, "Interim Financial Reporting" endorsed and issued into effect by the Financial Supervisory Commission of the Republic of China. Our responsibility is to express a conclusion on the consolidated financial statements based on our reviews.

Scope of Review

Except as explained in the Basis for Qualified Conclusion paragraph, we conducted our reviews in accordance with Statement of Standards on Review Engagements No.2410 "Review of Financial Information Performed by the Independent Auditor of the Entity". A review of the consolidated financial statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Basis for Qualified Conclusion

As stated in Note 6 (8), the equity accounted investments of BenQ Materials Corporation and its subsidiaries in the investee companies amounted to \$431,681 thousand and \$240,662 thousand as of June 30, 2023 and 2022, respectively, as well as the equity in net earnings on the joint ventures using the equity method of \$7,393 thousand, \$30,221 thousand, \$16,906 thousand and \$56,923 thousand for the three months and the six months ended June 30, 2023 and 2022, respectively, respectively, were recognized solely on the financial statements prepared by the investee companies, but not reviewed by independent auditors.

Qualified Conclusion

Based on our reviews, except for the effect of such adjustments, if any, as might have influenced by the financial statements of certain investee companies described in the Basis for Qualified Conclusion paragraph which were not reviewed by independent auditors, nothing has come to our attention that causes us to believe that the accompanying consolidated financial statements do not present fairly, in all material respects, the consolidated financial position of BenQ Materials Corporation and its subsidiaries as of June 30, 2023 and 2022, and the consolidated financial performance for the three months and the six months ended June 30, 2023 and 2022, and the consolidated cash flows for the six months ended June 30, 2023 and 2022, and the Preparation of Financial Reports by Securities Issuers" and IAS No. 34 "Interim Financial Reporting" as endorsed by the Financial Supervisory Commission of the Republic of China.

KPMG Taipei, Taiwan, Republic of China

Philips Tang

CPA:

Steven Shih

Approved audit number: FSC (6) No. 0940100754 Approved audit number: FSC (audited) No. 1060005191 August 2nd, 2023

Consolidated Balance Sheets

June 30, 2023, December 31 and June 30, 2022

(Unit: NT\$ thousand)

		June 30, 2023		December 31, 2022		June 30, 2022	
	Assets	 Amount	%	Amount	%	Amount	%
	Current assets:						
1100	Cash and cash equivalents (Note6 (1))	\$ 1,104,702	6	653,134	5	229,384	2
1110	Financial assets at fair value through profit or loss –						
	Current (Note 6 〔2〕)	-	-	17,316	-	1,230	-
1120	Financial assets at fair value through other						
	comprehensive income - Current (Note 6 $[$ 3 $]$)	64,713	-	54,549	-	63,941	I
1170	Notes and accounts receivable, net (Note 6 $\left(4 ight)$ and $\left($						
	23])	2,581,022	13	2,156,403	16	2,377,119	19
1180	Notes and accounts receivable - Related parties, net						
	amount (Note 6 $[4]$, $[23]$ and 7)	1,006,321	5	853,146	6	850,754	7
1200	Other receivables (Note 6 $[4]$ and $[5]$)	129,198	I	141,119	I	134,683	I
1210	Other receivables - Related parties (Note 6 $\left(\ 5 \ ight)$ and 7)	51,386	-	10	-	39,345	-
1310	Inventories net (Note 6 $\begin{bmatrix} 6 \end{bmatrix}$)	2,914,535	15	2,719,984	20	2,681,270	21
1479	Other current assets	285,153	I	209,242	2	233,410	2
1476	Other financial assets – Current (Note 8)	253,141	I	52,052	-	42,060	-
1460	Non-current assets held for sale (Note 6 $\left(7 \right)$)	 -				301,762	2
	Total current assets	 8,390,171	42	6,856,955	50	6,954,958	55
	Noncurrent assets:						
1517	Financial assets at fair value through other						
	comprehensive income – Non-current (Note 6 $[$ 3 $]$)	96,050	-	96,504	I	11,473	-
1550	Investment accounted for using equity method (Note 6						
	[8])	431,681	2	480,749	4	240,662	2
1600	Real estate, plant, and equipment (Note 6 $$ [II] , 7 and						
	8)	9,648,729	48	5,064,453	37	4,824,610	38
1755	Right-of-use asset (Note6 $[12]$)	838,246	4	569,198	4	141,815	I
1760	Net Investment property (Note 6 $\left[\begin{array}{c} I3 \end{array} \right]$)	151,247	I	161,272	I	168,475	I
1780	Intangible assets (Note 6 [9] , [14] and 7)	184,170	I	141,383	I	155,990	I
1840	Deferred tax assets	281,941	2	262,820	2	183,388	2
1920	Guarantee deposits paid	16,112	-	26,268	-	26,720	-
1980	Other financial assets –Non-current (Note 8)	9,252	-	-	-	-	-
1995	Other non-current assets	68,527	-	44,966	-	53,274	-
	Total non-current assets	 ١١,725,955	58	6,847,613	50	5,806,407	45
	Total assets	\$ 20,116,126	100	13,704,568	100	12,761,365	100

(See the attached notes to the Consolidated Financial Statements)

Chairman: Zhien-Chi (Z.C.) Chen

General Manager: Ray, Liu

Consolidated Balance Sheets

June 30, 2023, December 31 and June 30, 2022

(Unit: NT\$ thousand)

		June 30, 2023		December 31, 2022		June 30, 2022		
		Amount	%	Amount	%	Amount	%	
	Current liabilities:							
2100 2120	Short-term borrowings (Note 6 〔15〕) Financial liabilities at fair value through profit	\$ 650,000	4	1,051,460	8	478,320	4	
	or loss – Current (Note 6 $[2]$)	41,603	-	1,800	-	37,990	-	
2170	Accounts payable	2,810,766	14	2,541,222	19	2,803,153	22	
2180	Accounts payable – Related parties (Note 7)	51,470	-	34,905	-	73,604	I	
2200	Other payables (Note 6 $[9]$ and $[24]$)	1,830,595	9	1,527,559	11	1,636,292	13	
2216	Dividends payable (Note 6 [21] and 7)	641,349	3	-	-	481,012	4	
2220	Other payables – Related parties (Note 7)	23,652	-	20,098	-	23,916	-	
2320	Long-term borrowings due within one year							
	(Note 6 [16] and 8)	247,865	I	181,486	I	62,127	-	
2281	Lease liabilities – Current (Note 6 〔17〕)	12,208	-	7,787	-	7,829	-	
2282	Lease liabilities – Related parties – Current							
	(Note 6 [17] and 7)	92,570	I	91,746	I	46,395	-	
2399	Other current liabilities (Note 6 [7] and [
	23〕)	173,243	1	170,683	1	393,691	3	
	Total current liabilities	6,575,321	33	5,628,746	41	6,044,329	47	
	Non-current liabilities							
2540	Long-term borrowings (Note 6 [16] and 8)	4,130,702	21	1,084,002	8	1,204,273	10	
2570	Deferred tax liabilities	497,793	2	268,184	2	140,736	I	
2581	Lease liabilities – Non-current (Note 6 $[17]$)							
		43,619	-	44,595	-	48,510	-	
2582	Lease liabilities – Related parties – Non-							
	current (Note 6 $[17]$ and 7)	336,288	2	382,780	3	755	-	
2600	Other non-current liabilities (Note 6 [16])	49,830		45,616		49,683	<u> </u>	
	Total non-current liabilities	5,058,232	<u> </u>	1,825,177	<u> </u>	1,443,957	12	
	Total liabilities	11,633,553	58	7,453,923	54	7,488,286	59	
3110	Equity (Note 6 [21]): Common stock	3,206,745	16	3,206,745	23	3,206,745	25	
3200	Capital reserve	192,352	16	192,352	23	5,808	25	
3200	Retained earnings:	172,332	I	172,352	2	3,808	-	
3310	Legal reserve	540,821	3	414,305	3	414,305	3	
3320	Special reserve	68,835	-	103,309	I	103,309	I	
3350	Undistributed earnings	1,660,555	8	2,200,624	16	1,489,972	12	
3400	Other equity	(115,209)	-	(68,835)	(1)	(55,720)	(1)	
	Total equity attributable to the owners of						<u>_</u>	
	parent company	5,554,099	28	6,048,500	44	5,164,419	40	
36XX	Non-controlling (Note 6 [9], [10] and [
	21])	2,928,474	14	202,145	2	108,660	I	
	Total equity	8,482,573	42	6,250,645	46	5,273,079	41	
	Total liabilities and equity	\$ 20,116,126	100	13,704,568	100	12,761,365	100	

(See the attached notes to the Consolidated Financial Statements)

Chairman: Zhien-Chi (Z.C.) Chen

General Manager: Ray, Liu

Consolidated Statements of Comprehensive Income

For the Three and Six Months Ended June 30, 2023 and 2022

			he Three M	•••••	· · · · •	- <u> </u>	For the Six Months Ended June 30				
		2023		2022			2023		2022		
		Amount	%		Amount	%	Amount	%	Amount	%	
4000 5000	Net sales revenue (Note 6 〔 23 〕, 7 and 14) Operating cost	\$ 4,635,0	46 10	00	4,111,680	100	8,701,990	100	8,275,740	100	
	(Note [6], [11], [12], [13], [14], [17], [19], [24] 7 and 12)	(3,817,1	51) (8	2)	(3,266,478)	(79)	(7,185,025)	(83)	(6,675,386)	(81)	
	Gross operating profit	817,8		<u></u>	845,202	21	1,516,965	17	1,600,354	(81) 19	
	Operating expenses: (Note 6 [4], [11], [12], [14], [17]], [19], [24], 7 and 12):		<u></u>	<u> </u>			1,510,705				
6100	Selling expenses	(333,8	90) (8)	(310,858)	(8)	(622,443)	(7)	(588,224)	(7)	
6200	General and administrative expenses	(86,6	71) (1	2)	(80,082)	(2)	(169,471)	(2)	(157,654)	(2)	
6300	Research and development expenses	(238,1	09) (5)	(209,041)	(5)	(448,756)	(5)	(403,001)	(5)	
		(658,6	70) (1	5)	(599,981)	(15)	(1,240,670)	(14)	(1,148,879)	(14)	
	Net operating income	159,2	25	3	245,221	6	276,295	3	451,475	5	
	Non-operating income and expenses (Note 6 [7], [8], [16], [17], [25] and 7):										
7100	Interest revenue	6,0	- 43		575	-	12,576	-	1,147	-	
7010	Other revenue	24,0	33	I	6,539	-	27,051	I	7,796	-	
7020	Other profits and loss	62,2		2	50,752	I	37,123	I	156,582	2	
7050	Financial cost	(30,8	57) (I)	(14,741)	-	(60,403)	(1)	(25,581)	-	
7370	Share of profits of associates accounted for using the equity method		93 -		30,221	<u> </u>	16,906	-	56,923	<u> </u>	
		68,8		2	73,346	2	33,253	<u> </u>	196,867	3	
	Income before income tax	228,0		5	318,567	8	309,548	4	648,342	8	
7950	Less: Income tax expense (Note 6 [20])	(46,9	· · · ·	I)	(59,051)	(2)	(65,747)	(1)	(98,443)	(1)	
	Net profit	181,0	88	4	259,516	6	243,801	3	549,899	7	
	Other comprehensive income:										
8310	Items that will not be reclassified to profit or loss (Note 6 $[$ 21 $]$ $)$										
8316	Unrealized profit (loss) on investments in equity instruments at fair										
	value through other comprehensive income	(2,1	37) -		6,434	-	9,710	-	8,450	-	
8349	Income tax related to items that will not be reclassified	-	-		-			-		-	
8360	Items that may be reclassified subsequently to profit or loss (Note	(2,1	37) -		6,434		9,710		8,450	-	
8361	6 [8] and [21]) Exchanges differences arising on translation of financial statements of										
8370	foreign operations Share of other comprehensive income of associates accounted for using	(54,4	56) (1)	(24,499)	-	(39,199)	(1)	37,983	-	
	the equity method	(9,0	15) -		(5,725)	-	(14,638)	-	1,156	_	
8399	Income tax related to items that may be reclassified	-	-		-	_	-	-	-	_	
	,	(63,4	71) (I)	(30,224)		(53,837)	(1)	39,139		
	Other Comprehensive Income (loss)	(65,6		<u>,</u> 1)	(23,790)		(44,127)	(1)	47,589	-	
8500		\$ 115,4	, .	3	235,726	6	199,674	2	597,488	7	
	Net profit after tax for the period attributable to:										
8610	Owners of the parent company	\$ I 43,7 [°]	9 0	3	261,729	6	193,623	2	554,512	7	
8620	Non-controlling interests	37,2	98	I	(2,213)	-	50,178	I	(4,613)	-	
		\$ 181,0	88	4	259,516	6	243,801	3	549,899	7	
	Total comprehensive income attributable to:										
8710	Owners of the parent company	\$ 75,3	15	2	237,939	6	147,249	2	602,101	7	
8720	Non-controlling interests	40,1	65	<u> </u>	(2,213)	-	52,425	-	(4,613)	-	
		\$ 115,4	BO	3	235,726	6	199,674	2	597,488	7	
	Earnings per share (Unit: NT\$, Note 6 [22])										
9750	51	\$ 0.			0.82	=	0.60	-	1.73		
9850	Diluted earnings per share	\$ 0.	45		0.81		0.60		1.71		

(See the attached notes to the Consolidated Financial Stat

Chairman: Zhien-Chi (Z.C.) Chen

General Manager: Ray, Liu

Consolidated Statements of Changes in Equity

For the Six Months Ended June 30, 2023 and 2022

(Unit: NT\$ thousand)

				Pi	rofit and / loss a	ttributable to t	the owners of par	ent company					
								Other equi	ty items				
	Common stock	Capital reserve	Retained e Legal reserve	arnings Special reserve	Undistribute d earnings	Total	Exchange differences arising on translation	Unrealized profits and losses of financial assets at fair value through other comprehensive income	Remeasuremen t of defined welfare plan	Total	Total equity attributable to the owners of parent company	Non-controlling	Total equity
Balance as of January 1, 2022	\$ 3,206,745	5,808	317,262	83,534	1,533,290	1,934,086	(51,470)	(22,910)	(28,929)	(103,309)	5,043,330	113,273	5,156,603
Appropriation and distribution of retained earnings:													
Account for legal reserve	-	-	97,043	-	(97,043)	-	-	-	-	-	-	-	-
Account for special reserve	-	-	-	19,775	(19,775)	-	-	-	-	-	-	-	-
Cash dividend of common stock	-	-	-	-	(481,012)	(481,012)	-	-	-	-	(481,012)	-	(481,012)
Net profit	-	-	-	-	554,512	554,512	-	-	-	-	554,512	(4,6 3)	549,899
Other Comprehensive Income (Loss)				-		<u> </u>	39,139	8,450		47,589	47,589		47,589
Total comprehensive income for the period	-	-	-	-	554,512	554,512	39,139	8,450	-	47,589	602,101	(4,613)	597,488
Balance as of June 30, 2022	\$ 3,206,745	5,808	414,305	103,309	1,489,972	2,007,586	(12,331)	(14,460)	(28,929)	(55,720)	5,164,419	108,660	5,273,079
Balance as of January 1, 2023	\$ 3,206,745	192,352	414,305	103,309	2,200,624	2,718,238	(5,823)	(28,805)	(34,207)	(68,835)	6,048,500	202,145	6,250,645
Appropriation and distribution of retained earnings:													
Account for legal reserve	-	-	126,516	-	(126,516)	-	-	-	-	-	-	-	-
Reversal of special reserve	-	-	-	(34,474)	34,474	-	-	-	-	-	-	-	-
Cash dividend of common stock	-	-	-	-	(641,349)	(641,349)	-	-	-	-	(641,349)	-	(641,349)
Changes in the ownership equity recognized by the subsudiary	-	-	-	-	(301)	(301)	-	-	-	-	(301)	301	-
Capital injection in the non- controlling interest from the													
shareholder	-	-	_	_	-	_	-	_	-	_	_	2,016	2,016
Increase in non-controlling													
Distribution of cash dividednd to the non-controlling from the	-	-	-	-	-	-	-	-	-	-	-	3,014,587	3,014,587
subsidiary	-	-	-	-	-	-	-	-	-	-	-	(343,000)	(343,000)
Net profit	-	-	-	-	193,623	193,623	-	-	-	-	193,623	50,178	243,801
Other Comprehensive Income (Loss)	-	-	_	-	-	-	(56,084)	9,710	-	(46,374)	(46,374)	2,247	(44,127)
Total comprehensive income for the						·	. /			. ,			
period	-	-	-	-	193,623	193,623	(56,084)	9,710	<u> </u>	(46,374)	147,249	52,425	199,674
Balance as of June 30, 2023	\$ 3,206,745	192,352	540,821	68,835	1,660,555	2,270,211	(61,907)	(19,095)	(34,207)	(115,209)	5,554,099	2,928,474	8,482,573

(See the attached notes to the Financial Consolidated Statements)

Chairman: Zhien-Chi (Z.C.) Chen

General Manager: Ray, Liu

Consolidated Statements of Cash Flows

For the Six Months Ended June 30, 2023 and 2022

(Unit: NT\$ thousand)

	 the Six Months E	-	
	 2023	2022	
ash flows from operating activities:			
Income before income tax for the period	\$ 309,548	648,342	
Adjusted item:			
Depreciation expenses	444,883	298,352	
Amortization expenses	24,282	29,973	
Expected credit losses from reverse benefits	(12,834)	(10	
Valuation loss on financial liabilities measured at fair value through net profit or	57,119	33,307	
loss			
Interest expenses	60,403	25,58	
Interest revenue	(12,576)	(1,147	
Share of profit of affiliated companies accounted under the equity method	(16,906)	(56,923	
Loss (profits) from disposal of real estate, plant and equipment	(224)	I 2,903	
Profits from disposal of non-current assets held for sale	-	(109,790	
Amortization of deferred expenses transferred tp expenses	89,043	76,82	
Amortization of syndication fee costs	856	2,91	
Total adjustments to reconcile profit (loss)	634,046	311,98	
Changes in operating assets / liabilities:			
Net changes in operating assets:			
Notes and accounts receivable	(146,261)	(129,108	
Notes and accounts receivable – related parties	(135,996)	(186,694	
Other receivables	4,687	263	
Other accounts receivable – related parties	(40)	IC	
Inventory	68,154	126,598	
Other current assets	(81,056)	(13,885	
Total net changes in operating assets	 (290,512)	(202,816	
Net changes in operating liabilities:			
Accounts payable	189,343	(338,032	
Accounts payable – related parties	16,565	25,168	
Other payables	(112,122)	(9,588	
Other payables - related parties	3,554	(192	
Other current liabilities	(24)	28,202	
Net defined benefit liability	(654)	(972	
Other non-current liabilities	(223)	-	
Total net changes in operating liabilities	96,439	(295,414	
Total net changes in operating assets and liabilities	 (194,073)	(498,230	
Total adjustments	 439,973	(186,245	
Cash inflow generated from operations	 749,521	462,09	
Interest received	12,576	1,14	
Interest payment	(60,178)	(25,534	
Income tax paid	(155,414)	(125,963	
Net cash inflow from operating activities	 546,505	311,747	

(Continued on the next page)

Consolidated Statements of Cash Flows (Continued) For the Six Months Ended June 30, 2023 and 2022

(Unit: NT\$ thousand)

	For the Six Months Ended June			
		2023	2022	
Cash flows from investing activities:				
Acquisitions of financial assets at fair value through other comprehensive income	\$	-	(2,286)	
Net cash inflows from merger of subsidiaries		(1,464,838)	-	
Sale of non-current assets held for sale		-	273,699	
Acquisition of real estate, plant and equipment		(701,245)	(579,735)	
Disposal of real estate, plant and equipment		224	221	
Decrease in refundable deposits		17,542	2,254	
Acquisition of intangible assets		(18,976)	(17,242)	
Decrease (increase) in other financial assets		(201,089)	45,024	
Advance receipts increase on disposal of property, plant and equipment		-	150,416	
Increase in other non-current assets		(30,717)	(37,318)	
Net cash outflow from investing activities		(2,399,099)	(164,967)	
Cash flows from financing activities:				
Decrease in short-term loans		(401,460)	(108,529)	
Proceeds from long-term borrowings		4,240,200	262,850	
Repayments of long-term borrowings		(1,119,639)	(303,365)	
Ddecrease in deposits received		(2,981)	(5,785)	
Repayments of lease principal		(53,377)	(49,714)	
Capital increase of subsidiary by non-controlling interest shareholders		2,016	-	
Issuance of cash dividends to the non-controlling from subsidiary		(343,000)	-	
Net cash inflow (outflow) from financing activities		2,321,759	(204,543)	
Impact on exchange rates changes		(17,597)	9,020	
Increase (decrease) in cash and cash equivalents for the period		451,568	(48,743)	
Cash and cash equivalents at the beginning of the year		653,134	278,127	
Cash and cash equivalents at the end of the year	\$	1,104,702	229,384	

(See the attached notes to the Consolidated Financial Statements)

Chairman:	General Manager:	Accounting Manager:
Zhien-Chi (Z.C.) Chen	Ray, Liu	James, Wang

BENQ MATERIALS CORPORATION AND SUBSIDIARIES Notes to Consolidated Financial Statements For the Six Months Ended June 30, 2023 and 2022 (Unless otherwise indicated, the unit for all amounts is in NT\$ thousand.)

I. Company History

BenQ Materials Corporation (hereinafter referred to as "the Company," formerly known as Daxon Technology Inc. and had renamed in June, 2010) was established on July 16, 1998, with the approval of the Ministry of Economic Affairs. The registered address is No. 29, Jianguo E. Rd., Guishan Dist., Taoyuan City 333403, Taiwan (R.O.C.). The main business items of the Company and its subsidiaries (hereinafter referred to as "the Combined Company") are manufacturing and sales of film sheet products and medical equipment.

2. Date and Procedures of Authorization of Financial Statements

The Consolidated Financial Statements were published upon approval by the Board of Directors on August 2, 2023.

3. Application of New, Amended and Revised Accounting Standards and Interpretations

(1) The Impact of adopting newly released and revised standards and interpretations endorsed by the Financial Supervisory Commission (hereinafter referred to as "FSC").

The Combined Company has been applied to the application of the newly recognized IFRSs specified above will not have a material impact on the Consolidated Financial Statements since January 1, 2023.

- Amendments to IAS I "Disclosure of the Accounting Policy"
- Amendments to IAS 8 "Definition of the Accounting Evaluation"
- Amendments to IAS 12 "Related to Referred Tax Assets and Liabilities from Unity Transaction"

(2) Newly issued and revised standards and interpretations are not yet endorsed by FSC

The standards and interpretations have been issued and amended by IASB that are not yet recognized by FSC, they maybe relate to Combined Company as follows:

New or amended standards	Major amendments	The effective date of issuance by IASB
Amendments to IAS I	The current IAS I stipulates that liabilities for which an	January I, 2024
"Classification of Liabilities as	enterprise has not unconditionally deferred the	
Current or Non-Current"	repayment period to at least 12 months after the	
	reporting period shall be classified as current. The	
	amendment to deletion of the right should be	
	unconditional, stipulating that the right must exist on	
	the end date of the reporting period and mustbe	
	material.	
	The amendments clarify how companies should classify	
	liabilities repaid by issuing their own equity instruments	
	(such as convertible bonds)	

		The effective date of
New or amended standards	Major amendments	issuance by IASB
Amendments to IAS I "The	After renewing to consider that some parts of IAS I are	January I, 2024
Contractual Clauses of Non-	amended in 2020, The new amendments clarify only the	
Current Liabilities"	contractual clauses which is followed before the	
	reporting period could affect the classification of liabilities	
	under the current or non-current.	
	The enterprise must follow the contractual clauses (the	
	clauses in the future) that don't affect the classification of	
	liabilities after the reporting period. Only the non-	
	current liabilities are limited by the contractual clauses in	
	the future, the enterprise have to disclose the	
	information so as to aid the user of the financial report	
	understand the liabilities maybe have the risk of the	
	repayment within 12 months after the reporting period.	

The Combined Company is continuously evaluating the aforementioned standards and interpreting the financial status and impact of the operating results for the Combined Company. Besides, the relevant impact will be disclosed when the evaluation is completed.

The Combined Company expects that the following other newly issued and revised standards that have not yet been approved by the FSC will not have a significant impact on the Consolidated Financial Statements.

- Amendments to IFRS 10 and IAS 28 "Sale or Contribution of Assets between an Investor and its Associate or Joint Venture"
- Amendments to IFRS 17 "Insurance Contract"
- Amendments to IFRS 16 "Lease Liabilities for Sale and Leaseback"
- Amendments to IAS 7 and IFRS 7 "Arrange for the financing of the Supplier"
- Amendments to IAS 12 "National Taxation Revolution Pillar 2 Model Rules"

4. Summary of Significant Accounting Policies:

(1) Statement of compliance

The consolidated financial statements of the Company have been prepared in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers (the "Regulations") and the International Accounting Standards 34, "Interim financial reporting" as endorsed by the FSC. The Company's accompanying consolidated financial statements have been prepared in accordance with the IFRSs, IASs, IFRIC Interpretations, and SIC Interpretations endorsed and issued into effect by the FSC (collectively as "Taiwan-IFRSs").

Except for the following, the accounting policies applied in these consolidated financial statements are consistent with those applied in the consolidated financial statements for the year ended December 31, 2022. Refer to Note 4 for the consolidated financial statements for the year ended December 31, 2022 for the details.

(2) Basis of consolidation

I) List of subsidiaries in the Consolidated Financial Statements:

			Pro	oportion of	ownership((%)
Investment				Decembe		
company			June 30,	r 31,	June 30,	Descripti
name	Subsidiary name	Business type	2023	2022	2022	on
BenQ	BenQ Materials (L) Co. (BMLB)	Holding company	100.00	100.00	100.00	-
BenQ	Sigma Medical Supplies Corp. (Sigma-Medical)	Sale of medical equipment	100.00	100.00	100.00	-
		Development, manufacturing and sale of				
BenQ	Genejet Biotech Co., Ltd (Genejet)	medical equipment	70.00	70.00	70.00	-
BenQ	Cenefom Corp. (Cenefom)	Development, manufacturing and sale of				
BenQ	Ceneloni Corp. (Ceneloni)	medical equipment	50.98	51.34	34.83	-
		Development, manufacturing and sale of				
BenQ	Web-Pro Corp. (Web-Pro)	hygienic medical consumables and				
		equipment production	51.00	-	-	(Note I)
BMLB	BenQ Materials (Suzhou) Corp. (BMS)	Processing of functional film products	100.00	100.00	100.00	-
BMLB	Daxon Biomedical (Suzhou) Co., Ltd. (DTB)	Provision of services and sales of related				
DI'ILD	Daxon Biomedical (Suzilou) Co., Etd. (DTB)	products such as medical equipment	100.00	100.00	100.00	-
BMLB	BenQ Materials (Wuhu) Corp. (BMW)	Manufacture and sale of film sheet and				
DI'ILD	BenQ materials (wund) Corp. (Brive)	cosmetic-related	100.00	100.00	100.00	-
BMLB	BenQ Materials Medical (Suzhou) Co., Ltd. (BMM)	Manufacture and sale of medical				
DITLD	Beng Hatenais Hedical (Suzhou) Co., Etc. (BHH)	consumables and equipment	100.00	100.00	100.00	-
Sigma Madical	Suzhou Sigma Medical Supply Co., Ltd. (Suzhou					
Sigma-Medical	Sigma-Medical)	Sale of medical equipment	100.00	100.00	100.00	-
Web-Pro	Beyond Top Pte Ltd (WPSG)	Holding company	51.00	-	-	(Note I)
WPSG	Web-Pro (Vietnam) Co., Ltd (WPVN)	Manufacture and sale of hygienic medical				
**F3G		consumables and equipment production	51.00	-	-	(Note I)

Note I. On January 3, 2023 the Combined Company acquired the control of Web-Pro and it (Web-Pro) and its subsidiaries became a subsidiary; therefore, it was brought into the consolidated particular from that date.

2) List of subsidiaries which excluded in the Consolidated Financial Statements: None.

(3) Employee benefits

Pension cost for an interim period is calculated on a year-to-date basis by using the actuarially determined pension cost rate at the end of prior fiscal year, adjusted for significant market fluctuations subsequent to the end of prior fiscal year and for significant curtailments, settlements, or other significant one-time events.

(4) Income taxes

The Company measures and discloses interim period income tax expense in accordance with paragraph B12 of IAS 34, "Interim Financial Reporting". Income tax expense is best estimated by multiplying pre-tax income of the interim period by a projected annual effective tax rate and is recognized as current tax expense.

Income taxes that are recognized directly in equity or other comprehensive income are measured in respect of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the corresponding tax bases at the tax rates that are expected to be applied in the year in which the asset is realized or the liability is settled.

5. The Primary Sources of Uncertainties in Major Accounting Judgement Estimates and Assumptions

The preparation of the consolidated financial statements in conformity with the Regulations and IAS 34, "Interim Financial Reporting", as endorsed and issued into effect by the FSC requires management to make judgments, estimates and assumptions that affect the application of the accounting policies and the reported amount of assets, liabilities, income and expenses. The actual results may differ from these estimates.

In preparing the consolidated financial statements, critical accounting judgments and key sources of estimation uncertainty used by management in the application of accounting policies are consistent with those described in note 5 of the consolidated financial statements for the year ended December 31, 2022.

6. Description of Significant Accounts

Except as described below, the description of significant accounts in the accompanying consolidated financial statements is not materially different from those described in note 6 of the consolidated financial statements for the year ended December 31, 2022.

(1) Cash and Cash Equivalents

	Ju	ne 30, 2023	December 31, 2022	June 30, 2022
Working capital	\$	529	175	197
Demand deposit and cheque deposit		1,052,724	452,959	210,237
Time deposits with original maturity within three months		51,449	200,000	18,950
	\$	1.104.702	653,134	229,384

(2) Financial assets and liabilities at fair value through profit or loss - current

	June 30, 2023	December 31, 2022	June 30, 2022
Mandatory financial assets measured at fair value through profit or loss			
– current:			
Foreign exchange forward contracts	\$-	17,316	1,230
	June 30, 2023	December 31, 2022	June 30, 2022
Financial liabilities held for trading – current:	(\$32,735)	-	(34,415)
Foreign exchange forward contracts	(8,868)	(1,800)	(3,575)
Foreign exchange swaps	(\$41,603)	(1,800)	(37,990)

Fair value remeasurement was recognized in profit or loss. Refer to Note 6 [25] for details.

I) Derivatives

The Combined Company engages in derivative financial instrument transactions to avoid exchange rate risks exposed by business and financing activities. Because hedging accounting is not applied, the details of the derivative instruments of financial assets and liabilities measured at fair value through profit and loss are as follows:

a. Foreign exchange forward contracts

	June 30, 2023			
Contract amount				
(NT\$ thousands)	Type of currency	Due date		
USD <u>\$ 15,000</u>	Sell USD / Buy RMB	July 28, 2023		
USD <u>24,000</u>	Sell USD / Buy JPY	July 24, 2023~August 24, 2023		
	December 31, 2022			
Contract amount				
(NT\$ thousands)	Type of currency	Due date		
USD <u>\$ 30,000</u>	January 31, 2023			
USD <u>18,000</u>	Sell USD / Buy JPY	January 19, 2023~February 24, 2023		
	June 30, 2022			
Contract amount				
(NT\$ thousands)	Type of currency	Due date		
USD <u>\$ 16,000</u>	Sell USD / Buy RMB	July 29, 2022		
USD <u>32,400</u>	Sell USD / Buy JPY	July 22, 2022~August 24, 2022		
USD <u>10,000</u>	Sell USD / Buy NTD	July 22, 2022		
h. Fancian ayahanga ayana				
b. Foreign exchange swaps				
	June 30, 2023			
Contract amount				
Contract amount (NT\$ thousands)	Type of currency	Due date		
(NT\$ thousands)		July 28 2023~July 31, 202		
(NT\$ thousands)	Sell USD / Buy NTD	July 28 2023~July 31, 2023		
(NT\$ thousands) USD <u>\$ 52,00</u>	Sell USD / Buy NTD	July 28 2023~July 31, 2023		

	June 30, 2022	
Contract amount		
(NT\$ thousands)	Type of currency	Due date
USD <u>\$ 48,000</u>	Sell USD / Buy NTD	July 29, 2022

(3) Financial assets measured at fair value through other comprehensive income

	Jun	e 30, 2023	December 31, 2022	June 30, 2022
Equity instruments measured at fair value through other comprehensive income:				
Stocks listed in the emering stock market in Taiwan	\$	64,713	54,549	63,941
Unlisted stocks	•	96,050	96,504	11,473
	\$	160,763	151,053	75,414
Current	\$	64,713	54,549	63,941
Non-current		96,050	96,504	11,473
	\$	160,763	151,053	75,414

The Combined Company designated the aforementioned investments as the financial assets at FVTOCI because these equity instruments were held for the long-term strategical purposes and not for trading.

For the six months ended June 30, 2023 and 2022, no disposal of the aforementioned strategical investments for the Combined Company, and the accumulated profits and loss for the period weren't transferred within the equity.

(4) Notes and accounts receivable

			December 31,	
	Ju	ne 30, 2023	2022	June 30, 2022
Notes receivable	\$	30,717	3,87	27,763
Accounts receivable		2,572,560	2,176,243	2,369,075
Deduction: allowance for loss		(22,255)	(33,711)	(19,719)
		2,581,022	2,156,403	2,377,119
Accounts receivable - related parties		1,006,321	853,146	850,754
	\$	3,587,343	3,009,549	3,227,873

1) The Combined Company adopted a simplified approach to estimate expected credit losses for all note and account receivables (including related parties), that is, the expected credit losses during the lifetime are measured, and forward-looking information has been incorporated. The expected credit loss analysis of notes receivable and accounts receivable (including related-parties) of the Combined Company as of June 30, 2023, December 31 and June 30, 2022 was as follows:

June 30, 2023

	Carry	ing amount of		Loss allowance for
	accounts receivable		Weighted-average	lifetime expected
		and bills	loss rate	credit losses
Not past due	\$	3,570,062	0.0622%	2,219
Past due over I~30 days		17,211	4.7586%	819
Past due over 31~60 days		3,270	4.9541%	162
Past due over 91 days		19,055	100%	19,055
	\$	3,609,598		22,255

			December 31, 2022	
	Carry	ing amount of		Loss allowance for
	accou	nts receivable	Weighted-average	lifetime expected
		and bills	loss rate	credit losses
Not past due	\$	2,925,756	0.0278%	812
Past due over 1~30 days		28,997	1.4450%	419
Past due over 31~60 days		32,501	2.6891%	874
Past due over 61~90 days		25,652	4.8807%	1,252
Past due over 91 days		30,354	100%	30,354
	\$	3,043,260		33,711

	Carr	ying amount		
	0	faccounts		Loss allowance for
	receivable and Weighted-average		lifetime expected	
		bills	loss rate	credit losses
Not past due	\$	3,221,769	0%	-
Past due over 1~30 days		4,062	0.0492%	2
Past due over 31~60 days		1,833	0.3273%	6
Past due over 61~90 days		219	0.9132%	2
Past due over 91 days		19,709	100%	19,709
	\$	3,247,592		19,719

2) The table of changes in allowance loss for notes receivable and accounts receivable of the Combined Company is as follows:

	Six Months Ended June 30			
		2023	2022	
Balance at the beginning of the year	\$	33,711	19,316	
Effect of first-time incorporation of				
subsidiaries		2,447	-	
Impairment loss on reverse benefits		(12,834)	(10)	
Unrecoverable money offset for the				
period		(556)	-	
Gain and Loss of foreign exchange		(5 3)	413	
Balance at the end of the year	\$	22,255	19,719	

3) The Combined Company and the financial institution sign a non-recourse agreement for the sale of accounts receivable. According to the contract, the Combined Company does not have to bear the risk that the accounts receivable cannot be recovered, but only bears the losses caused by commercial disputes. Since the Combined Company has transferred almost all the risks and rewards of the ownership of the above accounts receivable and has not continued to participate in it, it has met the conditions for derecognizing financial assets. After derecognizing the claims on accounts receivable, the claims on financial institutions are listed in other receivables. Relevant information about undue factoring accounts receivable on the reporting date was as follows:

				June 30, 2023				
					Show as			
			Amount still		other	Range of		
			available in	Advance	receivables	interest	Other imp	ortant
Sale object	Sale	e amount	advance	amount	(Note 6 [5])	rates	matte	rs
Faipei Fubon Bank	\$	371,457	-	334,312	37,145	6.37%	None	
E.Sun Bank		161,133	-	145,019	16,114	6.16%	None	
	\$	532,590		479,331	53,259			
				December 31,	2022			
			Amount still		other	Range of		
			available in	Advance	receivables	interest	Other im	portant
Sale object	Sa	ale amount	advance	amount	(Note 6 [5])	rates	matt	ers
E.Sun Bank	\$	225,506	-	202,956	22,550	4.97~5.10%	None	
Taipei Fubon Bank		218,941	-	197,047	21,894	5.29%	None	-
							Guaranteed	
							promissory	
KGI Bank		57,962		52,166	5,796	5.73%	note	921,900
	\$	502,409		452,169	50,240		-	921,900
				June 30, 202	22			
			Amount still		other	Range of		
			available in	Advance	receivables	interest	Other im	portant
Sale object	Sa	ale amount	advance	amount	(Note 6 [5])	rates	matt	ers
Taipei Fubon Bank	\$	217,978	-	196,180	21,798	2.52%	Nor	ne
E.Sun Bank		198,133	-	178,320	19,813	2.31%	Nor	ne
							Guaranteed	
							promissory	
KGI Bank		146,772		132,095	14,677	2.55%	note	891,600
	\$	562,883	-	506,595	56,288			891,600

For the relevant information about the accounts receivable that meet the derecognition conditions - the transfer of creditor's rights of related parties, please refer to Note 7.

(5) Other receivables

	Jun	e 30, 2023	December 31, 2022	June 30, 2022
Other receivables – accounts				
receivable sale minus advance				
price balance (Note 6 [4] and				
7)	\$	123,490	137,650	133,890
Other receivables - dividends				
receivable - related parties		51,336	-	39,335
Other receivables - other		5,708	3,469	793
Other receivables - related				
parties		50	10	10
		180,584	4 , 29	174,028
Deduction: Allowance for loss		-	-	-
	\$	180,584	141,129	174,028

The Combined Company's other receivables as of June 30, 2023, December 31 and June 30, 2022, have no expected credit losses after assessment.

(6) Inventories

	June 30, 2023		June 30, 2023 December 31, 2022			June 30, 2022		
Raw materials	\$	1,276,721	1,090,770	1,166,226				
Work in process		857,556	786,853	738,680				
Finished goods		780,258	842,361	776,364				
	\$	2,914,535	2,719,984	2,681,270				

The details of inventory-related costs and expenses (gains) recognized in the cost of goods sold in the current period are as follows:

	Threee Months Ended June 30			Six Months Ended June 30			
		2023	2022	 2023	2022		
Inventories cost has been				 			
sold	\$	3,770,701	3,300,969	7,122,275	6,586,947		
Reversal of allowance for							
inventory market price							
decline		41,385	(40,412)	53,816	73,521		
	\$	3,812,086	3,260,557	\$ 7,176,091	6,660,468		

The loss on inventory is the inventory falling price loss recognized as net realizable value due to inventory write-down. Inventory falling price recovery benefit is due to the increase in the price of some raw materials for which allowance for falling price loss has been provided at the beginning of the period, or the inventory has been sold or used, resulting in a decrease in the amount of allowance for inventory falling price loss to be recognized.

(7) Non-current assets held for sale

	June 30), 2023	December 31,	2022	June 30, 2022
Land and structure held for sale	\$-		-		301,762

- 1) In May, 2021, the board of directors of SMS decided to sell the lands, structures, and equipment of machinery in Ruifang District, New Taipei City, and these assets on the carrying value was NT\$163,909 thousand. The sale transaction had been finished in the season first, 2022, and besides, the net price on the disposal of the assets was NT\$273,699 thousand, the derivative gains on the disposal was NT\$109,790 thousand, was listed under "the other profits and loss". Some of the machinery equipment was sold to the others-related of the Combined Company, refer to Note 7 for the details.
- 2) In July, 2021, the board of directors of BMS decided to sell parts of the real estate and assets-related (the land use rights, buildings, and machinery equipment on the book of first record and deferred expenses) located in the Industrial Park of Suzhou, Suzhou City, China. BMS had signed the bargains with the buyer in March, 2022, and sold the assets by RMB264,036 thousand (included fax), as of June 30, 2022, the advance amount was RMB52,807 thousand which was recorded under "other current liabilities", and the aforementioned assets on the carrying amount of \$301,762 thousand will be classified as the non-current held for sale. The aforementioned transaction had been finished for sale on the third season in 2022, besides, the net price on the disposal of the assets was NT\$1,079,231 thousand, the derivative gains on the disposal were NT\$780,563 thousand (the relevant to the land value increment tax and the income tax deduction), was listed under "The Other Profits and Loss", as of December 31, 2022, the relevant to the amount had received.

(8) Investments accounted by equity method

	June 3	80, 2023 (Not		June 30, 2022 (Not		
	ä	udited)	December 31, 2022	audited)		
Associates	\$	431,681	480,749	240,662		

I) Associate companies:

			Jun	June 30, 2023		December 31, 2022		June 30, 2022	
		Principal business place/ country of						Book amount(
Name of	Nature of Relationship with the	incorporati	Voting	Book amount	Voting	Book	Voting	not	
associates	Company	on	rights%	(not audited)	rights%	amount	rights%	audited)	
	Its main business is to manufacture and								
Visco Vision Inc.	sell disposable contact lenses, and it is a								
(Visco Vision)	strategic partner of the Company.	Taiwan	14.82%	422,870	14.82%	471,428	17.97%	232,611	
	Its main business is to research, develop								
MLK Bioscience	and sell medical devices, and it is a								
Co., Ltd. (MLK)	strategic partner of the Company.	Taiwan	20.00%	4,224	20.00%	4,347	20.00%	4,436	
Coatmed	Its main business is to sell medical								
Incorporation	devices, and it is a strategic partner of the								
(Coatmed)	Company.	Taiwan	9.98%	4,587	9.98%	4,974	20.00%	3,615	
				\$ 431,681	_	480,749		240,662	

In November 2022, the Company disposing of some of the equity of Visco with a cash amount of NT\$84,000 thousand resulting in disposal of an investment benefit of NT\$67,230 thousand. In addition, the consolidated company did not participate in the capital increase handled by Visco Vision in November 2022, which reduced the consolidated company's equity in Visco to 14.82% (but it did not result in a significant loss of influence), resulting in an increase in the capital surplus of NT\$184,705 thousand and a disposal investment loss of NT\$3,131thousand.

Coatmed Incorporation (hereinafter referred to as "Coatmed") made a cash capital increase in October 2022, and the Combined Company did not participate in the capital increase, which reduced the Combined company's interest in Coatmed to 9.98%. However, the Combined company still serves as a director of the company and participates in decision-making, so it has not lost significant loss of influence.

The share of net profit of the Combined Company for the three months and the six months ended June 30, 2023 and 2022 was \$7,393 thousand, \$30,221 thousand, \$16,906 thousand and \$56,923 thousand respectively.

The fair value of a listed related enterprise of significance to the Combined Company is as follows:

	June 30, 2023		December 31, 2022	June 30, 2023	
Visco Vision	\$	2,025,429	2,655,458	-	

The above ordinary shares of Visco Vision began to be listed on the Taiwan Stock Exchange on November 28, 2022.

The aggregate financial information of a related enterprise of material significance to the Combined Company is as follows:

a. Aggregated financial information of Visco Vision

	J	une 30, 2023	December 31, 2022	June 30, 2022
Current assets	\$	2,080,971	2,651,705	1,327,025
Non-current assets		2,810,717	2,642,290	2,291,945
Current liabilities		(1,168,532)	(956,308)	(1,137,287)
Non-current liabilities		(964,837)	(1,228,947)	(1,243,361)
Net assets	\$	2,758,319	3,108,740	1,238,322
Net assets attributable to non-				
controlling interests	\$	21,782	24,528	27,451
Net assets attributable to owners of				
the investee company	\$	2,736,537	3,084,212	1,210,871

	Three Months Ended June 30		d June 30	Six Months Ended June 30		
		2023	2022	2023	2022	
Operating revenue	\$	535,625	733.261	1,061,450	1,375,364	
Net profit for the current period		55,670	153,591	93,192	308,149	
Other comprehensive income(loss)		(85,772)	(30,854)	(97,113)	7,511	
Total comprehensive income		(\$30,102)	122,737	(3,921)	315,660	
Total comprehensive profit or loss						
attributable to non-controlling interests		(\$1,215)	(801)	(2,746)	(801)	
Total comprehensive profit or loss						
attributable to the owners of the						
investee company		(\$28,887)	123,538	(1,175)	316,461	

	Three Months Ended June 30			Six Months Ended June 30	
		2023	2022	2023	2022
Share in net assets of related enterprise of the					
Combined Company at the beginning of the period	\$	424,219	207,723	471,428	213,301
Net profit attributable to the Combined Company					
in the current period		7,679	30,620	17,428	57,484
Other comprehensive income(loss) attributable to					
the Combined Company in the current period		(9,028)	(5,732)	(14,650)	1,161
Dividends received from associates in the current					
period		-	-	(51,336)	(39,335)
Carrying amount on the equity at the end of period					
from the Company to the associate companies	\$	422,870	232,611	422,870	232,611

b. The aggregate financial information of individual insignificant related enterprises under the equity method of the Combined Company is as follows, and such financial information is the amount included in the consolidated financial report:

	June	30, 2023	December 31, 2022	June 30, 2022
The carrying amount of equity of				
individually immaterial associates				
at the end of the period	\$	8,811	9,321	8,05 I

	Three Months En	ided June 30	Six Months Ended June 30		
-	2023	2022	2023	2022	
Share attribuatable to the					
Combined Company:					
Net loss	(\$286)	(399)	(522)	(561)	
Other comprehensive					
income(loss)	13	7	12	(5)	
Total comprehensive income	(\$273)	(392)	(510)	(566)	

2) Investments accounted by equity method not reviewed

The Company's share of the profit and other comprehensive income from the investments accounted by equity method of the financial statements were not reviewed by independent auditors.

(9) Business merges

- 1) Acquisition of a subsidiary Web-Pro Corp. (Web-Pro) and its subsidiaries
- a. Acquisition of transfer consideration from subsidiaries

On January 3, 2023 (the acquisition date), the Combined Company bought the stocks of 51% from the shareholders of Web-pro by total amounted of 3,161,999 thousand and obtained the control over the company. Therefore, from the acquisition date onwards, the company was included in the Combined Company. Web-Pro and its subsidiaries are mainly engaged in the professional manufactured and processed of spunlace nonwoven and all kinds of PE breathable films. The Combined Company purchase Web-Pro and its subsidiaries are order to speed the layout for the group on the medical business and spread the core technology of research, development and manufacturer to the development of medical-related materials, and acquired the existing base customers and the overseas stronghold.

In addition, according to the rule of the stock transaction for the contract, the Combined Company should reserve 10% of the total amount for the transaction within six months after delivery and balance to compensate the seller by the clause of the contract. As of June 30, 2023, the reserved amount will total to 316,200 thousand and be listed under other payables.

b. Acquisition of identifiable net assets

The fair value of the identifiable assets acquired and liabilities assumed by Web-Pro on January 3, 2023 (acquisition date) are as follows:

Transfer consideration:			
Cash			\$ 3,161,999
Non-controlling interests (measured as identifiable	e		
net assets in proportion to non-controlling interes	ts)		3,014,587
Fair value of identifiable assets acquired and liabiliti	es		
assumed:			
Cash and Cash Equivalents	\$	۱,380,96۱	
Notes and accounts receivable, net		268,543	
Other receivables		6,926	
Inventories, net		262,705	
Other current assets		45,959	
Real estate, plant and equipment		4,279,751	
Right-of-use assets		329,406	
Intangible assets - patent		23,250	
Deferred tax assets		15,282	
Other financial assets - non-current		9,252	
Guarantee deposits paid		7,386	
Other non-current assets		35,041	

Goodwill		\$ 24,368
Other non-current liabilities	(590)	 (6,152,218)
Lease liabilities - non-current	(7,042)	
Deferred tax liabilities	(234,453)	
Other current liabilities	(2,584)	
Lease liabilities - current	(4,112)	
Other payables	(183,262)	
Notes and accounts payables	(80,201)	
(continued)		

The Combined Company will keep the above matters under review during the measurement period. If new information becomes available within one year of the acquisition date relating to facts and circumstances existing at the acquisition date that would identify an adjustment to the provisional amounts described above or any additional provision for abilities existing at the acquisition date, the accounting treatment for the acquisition will be modified.

3) Intangible assets

The above patent is amortized on a straight-line basis over 5 years, based on the expected future economic benefits.

The goodwill is mainly derived from the value of the human resources team of Web-Pro. These benefits do not meet the criteria for recognition as identifiable intangible assets and are not separately recognizes as goodwill, but the goodwill recognized is not expected to have any income tax effect.

4) Temporary information on the operating results

From the date of acquisition to June 30, 2023, the operating results of Web-Pro were consolidated into the consolidated statement of comprehensive income of the Combined Company, contributing operating income and net income after tax of NT\$1,169,935 thousand and NT\$108,794 thousand, respectively.

(10) The subsidiaries have the significant non-controlling equity

The significant non-controlling equity for subsidiaries to the Combined Company is as follows:

		Owenship equity of the non-controlling and the				
	Principal business					
Name of	place/ country of		December 31,			
subsidiaries	incorporation	June 30, 2023	2022	June 30, 2022		
Web-Pro	Taiwan	49.00%	-	-		

The aggregate financial information of above subsidiaries is as follows, the financial information is audited according to the IFRS which is recognized by Financial Supervisory Commission and have expressed the fair value which is adjusted by the Combined Company in the acquisition date, besides, the financial information is the amount which is not eliminate from the Combined Company before inter transaction:

I) Aggregated financial information of Visco Vision

	June 30, 2023			
Current assets	\$	1,546,460		
Non-current assets		4,613,113		
Current liabilities		(335,660)		
Non-current liabilities		(233,947)		
Net assets	\$	5,589,966		
The carrying amount of the controlling equity at the end of the				
period	\$	2,727,143		

	Three Months Ended June 30		Six Months Ended June 30	
		2023	2023	
Operating revenue	\$	629,580		1,169,935
Net profit for the current period	\$	75,326		108,794
Other comprehensive income(loss)		5,85 I		4,586
Total comprehensive income	\$	81,777	\$	113,380
Net profit attributable to non-controlling interests	\$	36,910	\$	53,309
Total comprehensive profit or loss attributable to non-				
controlling interests	\$	39,776	\$	55,556

	Six Mont	hs Ended June 30
		2023
Cash flow from operating activities	\$	I 58,899
Cash flow from investing activities		(206,988)
Cash flow from financing activities		(703,837)
Impact on exchanges rates changes		(4,164)
Decrease amount on cash and cash equivalents		(\$756,090)
Dividends payable for the non-controlling interests		(\$343,000)

(11) Real estate, plant and equipment

	Land		Housing and Buildings	Machinery equipment	Others	Total
Cost:						
Balance as of January 1, 2023	\$	1,344,108	3,625,582	6,350,404	2,958,091	14,278,185
Acquired from merging the						
companies	\$	2,655,099	1,444,443	I,789,372	486,722	6,375,636
Addition		152,115	76,178	47,132	425,658	701,083
Diposal		-	-	(628)	(1,805)	(2,433)
Reclassifications and effect of		27,672				
foreign exchange rate changes		27,072	(8,824)	54,456	(126,469)	(53,165)
Balance as of June 30, 2023	\$	4,178,994	5,137,379	8,240,736	3,742,197	21,299,306
Balance as of January 1, 2022	\$	1,344,108	3,585,151	6,137,565	2,324,470	13,391,294
Addition		-	10,567	89,124	475,343	575,034
Diposal		-	-	(186,974)	(9,661)	(196,635)
The non-current assets held for						(20,748)
sale to be reclassified		-	(4,430)	(6,3 8)	-	(20,748)
Other reclassifications and effect						
of foreign exchange rate						
changes		-	22,943	106,578	(86,279)	43,242
Balance as of June 30, 2022	\$	1,344,108	3,614,231	6,129,975	2,703,873	13,792,187
Accumulated depreciation:						
Balance as of January 1, 2023	\$	-	2,140,069	5,239,509	1,834,154	9,213,732
Acquired from merging the						
companies		-	369,842	1,488,106	237,937	2,095,885
Depreciation for the period		-	97,752	201,579	79,046	378,377
Disposal		-	-	(628)	(1,805)	(2,433)
Reclassifications and effect of						
foreign exchange rate changes		-	(17,146)	(15,683)	(2,155)	(34,984)
Balance as of June 30, 2023	\$	-	2,590,517	6,912,883	2,147,177	11,650,577
Balance as of January 1, 2022	\$	-	2,008,466	5,162,709	I,726,890	8,898,065
Depreciation for the period		-	61,484	125,100	55,655	242,239
Disposal		-	-	(173,850)	(9,661)	(183,511)
The non-current assets held for						
sale to be reclassified)		-	-	(16,318)	-	(16,318)
Other reclassifications and effect						
of foreign exchange rate						
changes	_	-	3,4 3	11,361	2,328	27,102
Balance as of June 30, 2022	\$	-	2,083,363	5,109,002	1,775,212	8,967,577
Carrying value:						
January I, 2023	\$	1,344,108	1,485,513	1,110,895	1,123,937	5,064,453
June 30, 2023	\$	4,178,994	2,546,862	1,327,853	1,595,020	9,648,729
January I, 2022	\$	1,344,108	1,576,685	974,856	597,580	4,493,229
June 30, 2022	\$	1,344,108	1,530,868	1,020,973	928,661	4,824,610
•		, ,	,,	, , ,		, , ,

For the details of real estate, plant and equipment that have been used as guarantee for long-term loans and financing lines, please refer to note 8 for details.

(12) Right-of-use assets

			Housing and	
	Land use right		buildings	Total
Right-of-use assets cost:				
Balance as of January 1, 2023	\$	57,125	543,255	600,380
Acquired from merging				
companies		401,619	1,977	403,596
Effect of changes in exchange rate		3		113
Balance as of June 30, 2023	\$	458,857	545,232	I,004,089
Balance as of January 1, 2022	\$	63,352	482,953	546,305
Addition		-	1,170	1,170
Reclassified as the non-current assets held for sale		(7,114)	-	(7,114)
Effect of changes in exchange rate		1,320	-	1,320
Balance as of June 30, 2022	\$	57,558	484,123	541,681
Accumulated depreciation of right-				
of-use assets:				
Balance as of January 1, 2023	\$	14,078	17,104	31,182
Acquired from merging	•	70 75 1	(20	74.100
companies	\$	73,751	439	74,190
Depreciation for the period		8,567	51,993	60,560
Effect of changes in exchange rate		(89)	-	(89)
Balance as of June 30, 2023	\$	96,307	69,536	165,843
Balance as of January 1, 2022	\$	15,035	340,980	356,015
Depreciation for the period		623	45,286	45,909
Reclassified as the non-current				
assets held for sale		(2,367)	-	(2,367)
Effect of changes in exchange rate		309	-	309
Balance as of June 30, 2022	\$	13,600	386,266	399,866
Carrying value:				
January I, 2023	\$	43,047	526,151	569,198
June 30, 2023	\$	362,550	475,696	838,246
January I, 2022	\$	48,317	141,973	190,290
June 30, 2022	\$	43,958	97,857	141,815

The land use right (including the land use right listed in investment real estate) is the Combined Company signed with the Mainland China Land and Resources Bureau to obtain the land use right of Suzhou Industrial Park and Gejiang District High-tech Industrial Development Zone in Wuhu City for the purpose of building factories. The period of using is from 2005 to 2055 and from 2012 to 2062. Besides, The Combined Company obtain the land use right to build the factories in KCN Nhon Trach III Industrial Park of Vietnam and the period of using is from 2016 to 2058.

(13) Investment property

	Ho	ousing and			
	b	ouildings	Land use right	Total	
Cost:					
Balance as of January 1, 2023	\$	308,385	59,477	367,862	
Effect of changes in exchange rate		(8,120)	(1,566)	(9,686)	
Balance as of June 30, 2023	\$	300,265	57,911	358,176	
Balance at January 1, 2022		890,396	67,711	958,107	
Reclassified as the non-current assets					
held for sale		(595,028)	(9,184)	(604,212)	
Effect of changes in exchange rate		15,355	1,400	16,755	
Balance at June 30, 2022	\$	310,723	59,927	370,650	
Accumulated depreciation:					
Balance as of January 1, 2023	\$	186,494	20,096	206,590	
Depreciation for the period		5,336	610	5,946	
Effect of changes in exchange rate		(5,061)	(546)	(5,607)	
Balance as of June 30, 2023	\$	186,769	20,160	206,929	
Balance as of January 1, 2022	\$	505,452	21,583	527,035	
Depreciation for the period		9,546	658	10,204	
Reclassified as the non-current assets					
held for sale		(341,222)	(3,056)	(344,278)	
Effect of changes in exchange rate		8,764	450	9,214	
Balance as of June 30, 2022	\$	182,540	19,635	202,175	
Carrying value:					
January I, 2023	\$	121,891	39,381	161,272	
June 30, 2023	\$	113,496	37,751	151,247	
January I, 2022	\$	384,944	46,128	431,072	
June 30, 2022	\$	128,183	40,292	168,475	

The fair value of the Company's investment property was not materially different from those disclosed in Note 6 [12] of the consolidated financial statements for the year ended December 31, 2022.

(14) Intangible assets

	G	oodwill	Patent	Patened techology	Customer relationship	Purchased software	Other	Total
Cost:				8/				
Balance as of January 1,								
2023	\$	32,262	-	127,248	34,925	296,034	1,864	492,333
Acquired from mergeing								
companies		24,368	23,250	-	-	-	-	47,618
Separate acquisition		-	-	-	-	18,976	-	18,976
Reclassification and effect								
of exchange rate changes		-	-	614	-	452	(26)	1,040
Balance as of June 30, 2023	\$	56,630	23,250	127,862	34,925	315,462	1,838	559,967
Balance as of January 1,								
2022	\$	32,262	-	122,173	34,925	264,009	1,850	455,219
Separate acquisition		-	-	-	-	17,242	-	17,242
Reclassification and effect								
of exchange rate changes		-	-	3,395	-	2,736	21	6,152
Balance as of June 30, 2022	\$	32,262	-	\$ 125,568	34,925	283,987	1,871	478,613
Accumulated amortization:								
Balance as of January 1,								
2023	\$	-	-	72,529	4,138	272,682	1,601	350,950
Amortization for the year		-	2,325	3,873	1,774	16,299	11	24,282
Reclassification and effect								
of exchange rate changes		-	-	614	-	(22)	(27)	565
Balance as of June 30, 2023	\$	-	2,325	77,016	5,912	288,959	1,585	375,797
Balance as of January 1,								
2022	\$	-	-	54,393	591	232,897	1,565	289,446
Amortization for the year		-	-	7,515	1,773	20,674	11	29,973
Reclassification and effect								
of exchange rate changes		-	-	3,166	-	17	21	3,204
Balance as of June 30, 2022	\$	-	-	65,074	2,364	253,588	1,597	322,623
Carrying amount:								
Balance as of January 1,								
2023	\$	32,262	-	54,719	30,787	23,352	263	141,383
Balance as of June 30, 2023	\$	56,630	20,925	50,846	29,013	26,503	253	184,170
Balance as of January 1,								
2022	\$	32,262	-	67,780	34,334	31,112	285	165,773
Balance as of June 30, 2022	\$	32,262	-	60,494	32,561	30,399	274	155,990

The Combined Company evaluate the deduction for loss to recycle amount for the goodwill during annual the financial report. The Combined Company performance the test of the deduction for loss in December 31, 2022, and goodwill didn't reduce the loss for the result, please refer to the note 6 [13] of consolidated financial statement in 2022.

In June 30, 2022, the anticipate operating revenue and the net profit (loss) of operating were evaluated to derivate cash for the goodwill, that didn't reduce the loss.

(15) Short-term borrowings

	Ju	ne 30, 2023	December 31, 2022	June 30, 2022
Unsecured bank notes	\$	650,000	1,051,460	478,320
Unused limit	\$	9,187,930	8,163,599	9,067,001
Interest rate range	1.80%~1.88%		1.37%~4.80%	1.23%~2.45%

(16) Long-term borrowings

	J	une 30, 2023	December 31, 2022	June 30, 2022	
Unsecured bank notes	\$	2,938,567	1,265,488	1,166,400	
Secured bank notes		I,440,000	-	100,000	
Less: Long-term					
borrowings due within					
one year		(247,865)	(181,486)	(62,127)	
Total	\$	4,130,702	I,084,002	1,204,273	
Unused limit	\$	6,398,340	5,796,100	5,769,150	
Expiry year (in year					
Republic of China)		112-122	112-119	112-119	
Interest rate range	1.75%~2.17%		1.63%~1.68%	1.25%~1.79%	

I) Borrowings and repayments

For the six months ended June 30, 2023 and 2022, the Company's borrow amount of long-term loan was \$4,240,200 thousand and \$262,850 thousand. For the six months ended June 30, 2023 and 2022, the Company's repayment amount of long-term loan principal was \$1,119,639 thousand and \$303,365 thousand.

2) Collateral for bank borrowings

Refer to note 8 for details on collateral pledged on secured bank borrowings.

3) Low interest loan from government

The combined Company obtained low-interest bank loans in accordance with the "Action Plan for Welcoming Overseas Taiwanese Business to Return to Invest in Taiwan" in 2020 and 2023. As of June 30, 2023, December 31, and June 30, 2022, the actual repayment preferential interest rate is 1.25%~1.60%, 1.13%~1.18% and 0.75%~0.80%, the actual amount of transfer amounted on \$2,198,910 thousand, \$1,278,350 thousand, and \$1,180,850 thousand. The fair value of the loans was \$2,163,835 thousand, \$1,253,770 thousand, and \$1,157,250 thousand based on the market interest rate of 1.75%~1.90%, 1.63%~1.68% and 1.25%~1.30%, besides, the difference of \$35,075 thousand, \$24,580 thousand, and \$23,600 thousand is regarded as the government subsidy and recognized as deferred income. For the three months and six months ended June 30, 2023 and 2022, the amount of the aforementioned deferred income transferred to "other income" amounted to \$1,616 thousand, \$1,168 thousand, \$3,013 thousand and \$2,304 thousand.

4) Financial ratio agreement in loan contract

According to the provisions of the joint loan contract with the bank, the Combined Company shall calculate and maintain the agreed current ratio, debt ratio and minimum tangible net worth, and other financial ratios during the duration of the loan in accordance with the annual Consolidated Financial Statements verified by the accountant. If the aforementioned financial ratios do not meet the agreed standards, the Combined Company may submit an exemption application and improvement plan to the management bank in accordance with the provisions of the joint loan contract. Most syndicated lending banks do not regard it as a breach of contract until they reach a resolution.

The financial ratios of the Combined Company as of December 31,2022, was in compliance with the agreed standards in the joint loan contract.

(17) Lease liabilities

The book value of the Combined Company's lease liabilities is as follows:

	June 30, 2023		December 31, 2022	June 30, 2022	
Current:					
Related parties	\$	92,570	91,746	46,395	
Non-related parties	\$	12,208	7,787	7,829	
Non-current:					
Related parties	\$	336,288	382,780	755	
Non-related parties	\$	43,619	44,595	48,510	

Please refer to note 6 [26] for the expiry analysis.

The amounts recognized in profit or loss were as follows:

	Thr	ee Months Er	nded June 30	Six Months Ended June 30		
	2023		2022	2023	2022	
Short-term lease expense	\$	4,274	3,520	8,287	6,166	
Interest expense of lease						
liabilities	\$	2,248	540	4,617	1,189	

The amounts in the statements of cash flows are as follows:

	Six Months Ended June 30		
		2023	2022
Total cash flows on lease	\$	66,281	57,069

I) Lease of housings and buildings

The Combined Company leases houses and buildings as factories and dormitories. The lease term of the plant is usually five to ten years. If the lease expires, a new contract and price must be negotiated, the Combined Company will reassess the relevant right-of-use assets and lease liabilities.

2) Other leases

The lease period for the part of the factory and automobiles that the Combined Company leases is one year. These leases are short-term leases. The Combined Company chooses to apply the exemption requirements and does not recognize its related right-of-use assets and lease liabilities.

(18) Operating leases - Leaser

There was no significant addition in the Company's operating lease contracts for the six months ended June 30, 2023 and 2022. Refer to Note 6 [17] for the Consolidated Financial Statements for the year ended December 31, 2022 for the details.

(19) Employee benefits

I) Defined benefit plans

Due to the report of December 31, 2022, there was no significant market volatility, significant curtailment, reimbursement and settlement or other significant one-time events. Therefore, the pension cost in the consolidated interim financial statements was measured and disclosed by the Company according to the pension cost valued by actuary as of December 31, 2022 and 2021.

The expenses recognized were as follows:

	Thre	e Months Er	nded June 30	Six Months Ended June 30		
	20	023	2022	2023	2022	
Operating cost	\$	50	15	88	30	
Operating expenses		44	14	78	27	
	\$	94	29	166	57	

2) Defined contribution plans

Pension expenses under the method of determining the appropriation of pensions are as follows:

	Th	ree Months En	ded June 30	Six Months Ended June 30		
	2023		2022	2023	2022	
Operating cost	\$	15,878	14,236	31,457	27,918	
Operating expenses		10,726	9,561	21,381	18,530	
	\$	26,604	23,797	52,838	46,448	

(20) Income taxes

I) Income tax expenses:

	Three Months Ended June 30			Six Months Ended June 30	
		2023	2022	2023	2022
Income tax for the period	\$	46,963	59,051	65,747	98,443

- 2) There was no income tax that was directly recognized in equity or other comprehensive profit or loss for the six months ended in June 30, 2023 and 2022.
- 3) The ROC income tax authorities have examined the Company's income tax returns through 2020.

(21) Capital and other equity

I) Common stock

As of June 30, 2023, and December 31 and June 30, 2022, the total value of nominal common stocks amounted to \$4,800,000 thousand, with a par value of NT\$ 10 per share, consisting of 480,000 thousand shares issued. There were 320,675 thousand shares of ordinary shares already issued.

2) Capital reserve

The details of capital surplus of the Combined Company were as follows:

	June	e 30, 2023	December 31, 2022	June 30, 2022
Changes in net equity of				
associates accounted for				
using equity method	\$	192,352	192,352	5,808

In accordance with the Company Act, the capital surplus generated from the premium of stock issuance and donation may only be used to offset accumulated deficits. The aforementioned realized capital reserve includes capital reserve resulting from premium on issuance of capital stock and earnings from donated assets received. In accordance with the provisions of the Regulations Governing the Offering and Issuance of Securities by Securities Issuers, the capital surplus may be capitalized, and the combined amount of any portions capitalized may not exceed 10% of the paid-in capital each year.

3) Retained earnings

According to the Company's Articles of Incorporation, if there is a surplus in the annual final accounts, tax should be paid first to make up for previous losses, 10% of the statutory surplus reserve should be raised, and the special surplus reserve should be set aside or converted according to laws and regulations. If there is still surplus and accumulate undistributed surplus, the Board of Directors shall draft a surplus distribution plan and submit it to the shareholders meeting for resolution and distribution.

If the aforementioned profits distribution proposal is based on cash dividends, the Board of Directors shall be authorized to make a resolution and report to the shareholders meeting.

According to the Company's Articles of Incorporation, the Company is a technological and capital-intensive industry that is in the midst of a growth period. In order to cooperate with a long-term capital planning and meet shareholders' demand for cash flow, the Company's dividend policy adopts a residual dividend policy to improve the Company's growth and sustainable operation. If the Company has a surplus after the annual final accounts, it shall pay taxes in accordance with the regulations to make up for the previous losses. The 10% of the second increase is the statutory surplus reserve, and after the special surplus reserve is drawn or converted in accordance with the law. If there is still a surplus, the dividend distribution shall not be less than 10% of the aforementioned calculated surplus. When dividends are distributed, in order to consider the needs of future expansion of the scale of operations and cash flow, the proportion of annual cash dividends shall not be less than 10% of the combined cash and stock dividends of the current year.

a. Legal reserve

When a company incurs no loss, it may, pursuant to a resolution to be adopted by a shareholders' meeting, distribute its legal reserve by issuing new shares or by cash, only the portion of legal reserve which exceeds 25% of the paid-in capital may be distributed.

b. Special reserve

According to FSC, when the Company distributes the distributable surplus, the net deduction of other shareholders' equity in the current year is reported. The amount of items other than the net profit after tax for the current period plus the net profit after tax for the current period is included in the undistributed earnings of the current period and the undistributed earnings of the previous period are set aside as special surplus reserves.; for the deduction of other shareholders' equity accumulated in the previous period, the same amount of special surplus reserve shall not be distributed from the undistributed surplus in the previous period. If other stockholders' equity deductions are reversed afterward, the reversal may be applicable for the appropriation of earnings.

c. Earnings distribution

The 2022 and 2021 distributions of earnings were resolved at the shareholders' meetings on February 23, 2023 and May 3, 2022. The dividends distributed to owners are as follows:

	2022			2021		
	ings per e(NT\$)	Amount		ings per e (NT\$)	Amount	
Cash	\$ 2.00	641,349	\$	1.50	481,012	

Relevant information can be inquired through channels such as public information observatories.

4) Other equity (after tax)

	Exchange differences arising on translation of financial statements of foreign operations	Remeasurement of definied welfare plan	Unrealized profit (loss) on investments in equity instruments at fair value through other comprehensive income	Total
January I, 2023	(\$5,823)	(34,207)	(28,805)	(68,835)
The exchange differences yielded by net assets of overseas operating institutions:	(43,523)	(31,207)	(20,000)	(00,000)
Consolidated company	(41,446)	-	-	(41,446)
Associates	(14,638)	-	-	(14,638)
Unrealized profit (loss) on investments in equity instruments at fair value through other				
comprehensive income			9,710	9,710
Balance as of June 30, 2023	(\$61,907)	(34,207)	(19,095)	(115,209)
Balance as of January I, 2022 The exchange differences	(\$51,470)	(28,929)	(22,910)	(103,309)
yielded by net assets of overseas operating institutions: Consolidated company Associates Unrealized profit (loss) on	37,983 1,156	- -	- -	37,983 1,156
investments in equity instruments at fair value through other comprehensive income	-	_	8,450	8,450
Balance as of June 30,				
2022	(\$12,331)	(28,929)	(14,460)	(55,720)

5) Non-controlling equity (after tax)

	Six Months Ended June 30		
		2023	2022
Balance at the beginning of the year	\$	202,145	3,273
Acquisition of subsidiaries		3,014,587	-
Share attributable to non-controlling interests:			
Net profit (loss) of the period		50,178	(4,613)
The exchange differences converted by the			
financial statement of overseas operating			
institutions:		2,247	-
Distribution the cash dividend to the non-			
controlling interest from the subsidiary		(343,000)	-
Capital injection in the non-controlling interest			
from the shareholder		2,016	-
Recognized as the changes in the ownership equity	Ý		
of subsidiaries		301	-
	\$	2,928,474	108,660

I) Basic earnings per share

	Three Months Ended June 30			Six Months Ended June 30		
		2023	2022	2023	2022	
Net profit attributable to						
holders of common equity of						
the Company	\$	143,790	261,729	193,623	554,512	
The weighted average number						
of shares outstanding						
(thousand shares)		320,675	320,675	320,675	320,675	
Basic earnings per share (in						
dollars)	\$	0.45	0.82	0.60	1.73	

2) Diluted earnings per share

	Three Months Ended June 30		Six Months Ended June 30		
		2023	2022	2023	2022
Net profit attributable to holders of					
common equity of the Company	\$	143,790	261,729	193,623	554,512
The weighted average number of					
shares outstanding (thousand shares)		320,675	320,675	320,675	320,675
Effect of potentially dilutive shares of					
common stocks (thousand shares):					
Employee bonuses		642	2,315	1,959	3,463
The weighted average number of					
shares outstanding (thousand shares)					
(After adjusting the number of					
dilutive potential common shares		321,317	322,990	322,634	324,138
Diluted earnings per share (in					
dollars)		0.45	0.81	0.60	1.71

(23) Revenue from contracts with customers

I) Disaggregation of revenue

	Three Months Ended June 30, 2023					
	Film s	Film sheet segment Medical segme		Total		
Primary geographical						
market:						
China	\$	2,304,744	301,637	2,606,381		
Taiwan		1,061,913	221,821	1,283,734		
USA		-	243,385	243,385		
Japan		17,637	198,489	216,126		
Others		19,163	266,257	285,420		
	\$	3,403,457	1,231,589	4,635,046		
Major products/services:						
Optoelectronics	\$	3,403,457	-	3,403,457		
Medical production		-	1,231,589	1,231,589		
	\$	3,403,457	1,231,589	4,635,046		

		Three Months Ended June 30, 2022					
	Film	sheet segment	Medical segment	Total			
Primary geographical							
market:							
China	\$	2,471,014	264,713	2,735,727			
Taiwan		1,017,599	111,398	1,128,997			
Others		106,552	I 40,404	246,956			
	\$	3,595,165	516,515	4,111.680			
Major products/services	:						
Optoelectronics	\$	3,595,165	-	3,595,165			
Medical production		-	516,515	516,515			
	\$	3,595,165	516,515	4,111,680			

		Six Mon	23	
	Film s	heet segment	Medical segment	Total
Primary geographical				
market:				
China	\$	4,323,193	510,419	4,833,612
Taiwan		2,052,035	423,957	2,475,992
USA		121	367,681	367,802
Japan		26,577	401,139	427,716
Others		38,550	558,318	596,868
	\$	6,440,476	2,261,514	8,701,990
Major products/services:				
Optoelectronics	\$	6,440,476	-	6,440,476
Medical production		-	2,261,514	2,261,514
	\$	6,440,476	2,261,514	8,701,990

		Six Months Ended June 30, 2022				
	Films	sheet segment	Medical segment	Total		
Primary geographical						
market:						
China	\$	4,872,637	471,614	5,344,251		
Taiwan		2,240,223	230,112	2,470,335		
Others		209,682	251,472	461,154		
	\$	7,322,542	953,198	8,275,740		
Major products/services:						
Optoelectronics	\$	7,322,542	-	7,322,542		
Medical production		-	953,198	953,198		
	\$	7,322,542	953,198	8,275,740		

2) Contract balances

	June	e 30, 2023	December 31, 2022	June 30, 2022
Notes and accounts				
receivable (including				
related parties)	\$	3,609,598	3,043,260	3,247,592
Deduction: Allowance for				
loss		(22,255)	(33,711)	(19,719)
Total	\$	3,587,343	3,009,549	3,227,873
		June 30, 20	023 December 31, 20	June 30, 2022
Contract liabilities (account	ed under			
other current liabilities)		\$ 68,	,405 56,	633 43,760

Refer to Note 6 (4) for details on accounts receivable and related loss allowance.

Amount of contract liabilities for the period starting from January I, 2023 and 2022, have been recognized as income for the six months ended June 30, 2023 and 2022 were NT\$46,180 thousand and NT\$38,395 thousand, respectively.

(24) Employee and directors' compensation

According to the Company's Articles of Incorporation, if there is any profit in the year, 5%-20% shall be allocated for employee compensation and no more than 1% for directors' compensation When there are accumulated losses, the Company shall offset the appropriate amounts before remuneration. The employee compensation in the preceding paragraph may include employees of affiliated companies who meet certain conditions for the payment of stocks or cash.

For the three and six months ended June 30, 2023 and 2022, BenQ accrued the remuneration to employees amounting to \$18,863 thousand, \$35,575 thousand, \$25,233 thousand and \$72,694 thousand, respectively, remuneration to directors amounting to \$1,415 thousand, \$2,668 thousand, \$1,893 thousand and \$5,452 thousand respectively, and the remuneration to directors were estimated based on the amount expected to pay and recognized together with the remuneration to employees as cost of sales or operating expenses. If there is a change in the proposed amounts after the annual consolidated financial statements are authorized for issue, the differences are accounted for as a change in accounting estimate and adjusted prospectively to next year's profit or loss.

Remuneration to employees for 2022 and 2021, in the amounting to \$165,978 thousand and \$134,276 thousand, respectively, remuneration to directors amounting to \$12,448 thousand and \$10,071 thousand, respectively, in cash for payment had been approved in the meeting of board of directors. The information about the remuneration to employees and directors is available at the Market Observation Post System website.

(25) Non-operating profit and loss

I) Interest revenue

	Th	Three Months Ended June 30		Six Months Ended June 30	
		2023	2022	2023	2022
Interest on bank deposits	\$	6,043	575	12,576	1,147

2) Other Income

	Three Months Ended June 30		Six Months Ended June 30		
		2023	2022	2023	2022
Government subsidy revenue	\$	24,033	6,539	27,051	7,796

3) Other gains and losses

	Three Months Ended June 30		Six Months Ended June 30		
		2023	2022	2023	2022
Disposal of real estate, plant					
and equipment interests					
(losses)	\$	224	(2,564)	224	(12,903)
Profits in the disposal of non-					
current assets held for sale					
(note 6 [7])		-	-	-	109,790
Net foreign currency exchange					
profits		186,786	192,071	165,305	272,915
Net loss from financial assets					
(liabilities) measured at fair					
value through profits (losses) -					
Derivative instruments		(128,287)	(142,296)	(141,397)	(219,338)
Others		3,491	3,541	12,991	6,118
	\$	62,214	50,752	37,123	156,582

4) Finance costs

	Three Months Ended June 30		Six Months Ended June 30	
	2023	2022	2023	2022
Interest expense of bank				
loans	(\$28,609)	(14,201)	(55,786)	(24,392)
Lease liabilities	(2,248)	(540)	(4,617)	(1,189)
	(\$30,857)	(14,741)	(60,403)	(25,581)

(26) Types of financial instruments and fair value

Except as described below, both the goals and policies of the Company's financial risk management and the Company's exposure to credit risk, liquidity risk and market risk were not materially different from those disclosed in Note 6 [25] [26] of the consolidated financial statements for the year ended December 31, 2022.

I) Types of financial instruments

a. Financial assets

	June 30, 2023	December 31, 2022	June 30, 2022
Financial assets at fair value through profit			
or loss:			
Foreign exchange forward contract	\$-	17,316	1,230
Financial assets at fair value through profit			
or loss	160,763	151,053	75,414
Financial assets measured at amortized cost:			
Cash and cash equivalents	1,104,702	653,134	229,384
Notes and accounts receivable and other			
receivables (including related parties)	3,767,927	3,150,678	3,401,901
Other financial assets - current and non-			
current	262,393	52,052	42,060
Guarantee deposits paid	16,112	26,268	26,720
Subtotal	5,151,134	3,882,132	3,700,065
Total	\$ 5,311,897	4,050,501	3,776,709

b. Financial liabilities

	June 30, 2023	December 31, 2022	June 30, 2023
Financial liabilities at fair value through profit			
or loss:			
Foreign currency forward contract	\$ 32,735	-	34,415
Foreign Exchange swaps	8,868	I,800	3,575
Subtotal	41,603	I ,800	37,990
Financial liabilities measured at amortized			
cost:			
Short-term borrowings	650,000	1,051,460	478,320
Notes and accounts payable and other			
payables (including related parties)	4,637,914	4,011,849	4,412,840
Dividends payable	641,349	-	481,012
Long-term borrowings (including loans			
due within one year)	4,378,567	I,265,488	1,266,400
Lease liabilities – current and non-			
current (including related parties)	484,685	526,908	103,489
Guarantee deposit received	10,309	12,923	20,127
Subtotal	10,802,824	6,868,628	6,762,188
Total	\$ 10,844,427	6,870,428	6,800,178

2) Liquidity risk

Current risk refers to the risk that the Combined Company fails to deliver cash or other financial assets to pay off financial liabilities and fails to fulfill relevant obligations. The Combined Company regularly monitors current and expected medium and long-term funding needs, and manages liquidity risks by maintaining sufficient cash and cash equivalents and bank financing lines, and ensuring compliance with the terms of the loan contract.

The unused loan amounts of the Combined Company as of June 30, 2023, December 31 and June 30, 2022 totaled \$15,586,270 thousand, \$13,959,699 thousand and \$14,836,151 thousand, respectively.

The following table illustrates the analysis of the remaining contractual maturity of financial liabilities during the agreed repayment period of the Combined Company, including interest payable, which is based on the earliest date on which the Combined Company may be required to repay and is compiled with undiscounted cash flows.
		ontractual	Within 6	(12 m	More than 5	
June 30, 2023	<u> </u>	ash flows	months	6-12 months	1-5 years	years
Non-derivative financial liabilities						
Short-term borrowings Accounts payable (including	\$	650,704	650,704	-	-	-
related parties) Other payables (including		2,862,236	2,862,236	-	-	-
related parties)		1,775,678	1,775,678	-	-	-
Dividends payable Long-term borrowings (including loans due within		641,349	641,349	-	-	-
one year) (floating rate) Lease liabilities (including		4,714,225	164,896	165,240	3,670,549	713,540
related parties)		506,088	54,424	58,190	374,888	18,586
Guarantee deposit received	\$	10,309	1,847 6,151,134	512 223,942	4,113 4,049,550	3,837 735,963
Derivative financial instruments	<u> </u>		-,,		-,,	
Foreign exchange forward contracts - total delivery:						
Inflow		(\$1,177,053)	(1,177,053)	-	-	-
Outflow		1,209,788	I,209,788	-	-	-
Foreign exchange swaps - net						
delivery		8,868	8,868		-	-
	\$	41,603	41,603		-	-
December 31, 2022						
Non-derivative financial liabilities Short-term borrowings Accounts payable (including	\$	1,056,403	854,991	201,412	-	-
related parties) Other payables (including		2,576,127	2,576,127	-	-	-
related parties) Long-term borrowings		1,435,722	1,435,722	-	-	-
(including loans due within one year) (floating rate) Lease liabilities (including		1,327,529	68,641	I 30,497	886,503	241,888
related parties)		552,720	54,080	54,086	423,025	21,529
Guarantee deposit received	\$	12,923 6,961,424	3,253 4,992,814	1,093 387,088	4,600 1,314,128	3,977 267,394
Derivative financial instruments						
Foreign exchange swaps - Net						
delivery	\$	1,800	1,800	-	-	-
June 30, 2022						
Non-derivative financial liabilities						
Short-term borrowings Accounts payable (including	\$	480,214	480,214	-	-	-
related parties) Other payables (including		2,876,757	2,876,757	-	-	-
related parties) Dividends payable		1,536,083 481,012	1,536,083 481,012	-	-	-
Long-term borrowings (including loans due within		401,012	401,012	-	-	-
one year) (floating rate) Lease liabilities (including		1,328,050	5,465	67,460	1,007,293	247,832
related parties)		107,825	50,908	4,536	27,910	24,47 I
Guarantee deposit received		20,127	1,104	986	16,484	1,553
	\$	6,830,068	5,431,543	72,982	1,051,687	273,856
Derivative financial instruments Foreign exchange forward contracts - total delivery:						
Inflow		(\$837,664)	(837,664)	-	-	-
Outflow		(\$837,004) 872,079	872,079	-	-	-
Foreign exchange swaps - net						
delivery	*	3,575	3,575		-	
	\$	37,990	37,990		-	-

The Combined Company does not expect that the occurrence timing of cash flow analyzed on due date would arrive significantly earlier, or the actual amount would significantly vary.

3) Exchange rate risk

The exchange rate risk of the Combined Company mainly comes from foreign currency denominated cash and cash equivalents, accounts receivable (payment) (including related parties), other receivables (payments) (including related parties), bank loans, etc. Foreign currency exchange gains and losses occur at the time of conversion. The book values of major monetary assets and liabilities of the Combined Company that are not denominated in functional currencies at the reporting date are as follows (including monetary items denominated in non-functional currencies that have been offset in the Consolidated Financial Statements):

Currency Unit: NT\$ Thousand

		J	une 30, 2023		
			New	Exchange	Profit and
	Foreign	Exchange	Taiwan	rate	loss
	currency	rate	Dollar	changes	impact
Financial assets		·			
Monetary items					
USD	\$ 170,239	31.100	5,294,433	1%	52,944
JPY	97,794	0.2148	21,006	1%	210
Financial liabilities					
Monetary items					
USD	70,584	31.100	2,195,162	1%	21,952
JPY	6,450,018	0.2148	I,385,464	۱%	13,855
		Dec	ember 31, 2	022	
			New	Exchange	Profit and
	Foreign	Exchange	Taiwan	rate	loss
	currency	rate	Dollar	changes	impact
Financial assets					
USD	\$ 129,516	30.730	3,980,027	1%	39,800
JPY	39,987	0.233	9,317	۱%	93
Financial liabilities					
USD	52,762	30.730	1,621,376	1%	16,214
JPY	5,803,273	0.233	1,352,163	۱%	13,522
		J	une 30, 2022		
			New	Exchange	Profit and
	Foreign	Exchange	Taiwan	rate	loss
	currency	rate	Dollar	changes	impact
Financial assets					
Monetary items					
USD	\$ 126,791	29.720	3,768,229	1%	37,682
JPY	281,266	0.2182	61,372	۱%	614
Financial liabilities					
Monetary items					
USD	56,913	29.720	1,691,454	۱%	16,915
JPY	6,973,513	0.2182	1,521,621	۱%	15,216

As the Company deal in diverse functional currencies, gains and losses on monetary items were summarized as a single amount. The aggregate of realized and unrealized foreign exchange (losses) gains for the three and six months ended June 30, 2023 and 2022, Refer to note 6 [25] for the details.

4) Fair value information

a. Financial instruments not measured at fair value

The management of the Combined Company believes that the financial assets and financial liabilities of the Combined Company classified as amortized cost is close to their fair value in the Consolidated Financial Statements.

b. Financial instruments measured at fair value

The following financial instruments are measured at fair value for the basis of repeatability. The table below provides an analysis of financial instruments measured subsequently to initial recognition at fair value, which are grouped into Levels I to 3 based on the degree to which the fair value is observable. Each level of the fair value hierarchy is defined as follows:

- a. Level I: Quoted prices (unadjusted) in active markets for identical assets or liabilities
- b. Level 2: Other than quoted prices included within Level I, inputs are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices).

c. Level 3: Derived from valuation techniques that include inputs for the asset or liability that are not based on observable market data (unobservable inputs).

	June 30, 2023							
				Fair V	air Value			
	Carry	ring amount	Level I	Level 2	Level 3	Total		
Financial assets at fair								
value through Other								
Comprehensive Income:								
Stocks listed in the								
emerging stock market in								
Taiwan	\$	64,713	-	64,713	-	64,713		
Non-listed Stocks		96,050	-	-	96,050	96,050		
	\$	160,763	-	64,713	96,050	160,763		
Financial liabilities at								
FVTPL:								
Foreign exchange forward								
contracts		(\$32,735)	-	(32,735)	-	(32,735)		
Foreign exchange swaps		(8,868)	_	(8,868)	-	(8,868)		
		(\$41,603)	-	(41,603)	-	(41,603)		
			Dec	ember 31, 2022 Fair V	ماييو			
	Carry	ring amount	Level I	Level 2	Level 3	Total		
Financial assets at FVTPL:								
Foreign exchange forward								
contracts	\$	17,316	-	17,316	-	17,316		
Financial assets at fair								
value through Other								
Comprehensive Income:	\$	54,549	-	54,549	-	54,549		
Stocks listed in the								
emerging stock market in								
Taiwan		96,504	-	-	96,504	96,504		
Non-listed Stocks	\$	151,053	-	54,549	96,504	151,053		
Financial liabilities at								
FVTPL:								
Foreign exchange swaps		(\$1,800)	-	(1,800)	-	(1,800)		

	June 30, 2022								
		Fair Value							
	Carrying amount	Level I	Level 2	Level 3	Total				
Financial assets at									
FVTPL:									
Foreign exchange									
forward contracts	\$ I,230	-	1,230	-	1,230				
Financial assets at fair									
value through Other									
Comprehensive									
Income:									
Stocks listed in the									
emerging stock market	t i								
in Taiwan	63,941	-	63,941	-	63,941				
Non-listed Stocks	11,473	-	-	11,473	11,473				
	75,414	-	63,941	11,473	75,414				
Financial liabilities at									
FVTPL:									
Foreign exchange									
forward contracts	(\$34,415)	-	(34,415)	-	(34,415)				
Foreign exchange									
swaps	(3,575)	-	(3,575)	-	(3,575)				
	(\$37,990)	-	(37,990)	-	(37,990)				

- 5) The assessment methods and assumptions followed for assessing fair value
 - a. Non-derivative financial instruments

If there is open quotation to financial instruments at active market, then the open quotation will be taken as fair value.

If the public quotation of a financial instrument can be obtained from an exchange, broker, underwriter, industry association, pricing service agency or competent authority in a timely and frequent manner, and the price represents the actual and regular fair market transactions, then the financial instrument has an active market quotation. If the aforesaid conditions fail, the market is not deemed as active.

The fair value of the domestic stocks held by the Combined Company is estimated based on the average transaction price of the stock market on the day.

The fair value of the Combined Company's holding of unlisted stocks for which no active market exists is estimated by using the market approach, which refers to the valuation of similar entities, the net worth of an entity and the operating performance. In addition, the significant unobservable inputs mainly comprise liquidity discount, in which the possible changes would not result in a potentially material financial effect. Therefore, the Company does not disclose the quantitative information.

b. Derivative financial instruments

It is evaluated with evaluation model widely accepted by market users. Forward exchange contracts and exchange contracts are usually valued based on current forward exchange rates.

6) Fair value level and transfer

The Combined Company did not have any financial assets and liabilities transferred in the fair value hierarchy for the six months ended June 30, 2023 and 2022.

7) Level 3 sheet of changes

Financial assets measured at fair value through other comprehensive profit and loss:

	Tł	ree Months En	ded June 30	Six Months Ended June 30		
		2023	2022	2023	2022	
Beginning balances	\$	96,305	11,473	96,504	9,187	
Purchase for the period		-	-	-	2,286	
Changes in other						
comprehensive profit and loss						
recognized in the current						
period	_	(255)	-	(454)	-	
Ending balances	\$	96,050	11,473	96,050	11,473	

(27) Financial risk management

Both the goals and policies of the Company's financial risk management were not materially different from those disclosed in Note 6[26] of the consolidated financial statements for the year ended December 31, 2022.

(28) Capital management

The objectives, policies and procedures of the Company's capital management have been applied consistently with those described in the consolidated financial statements for the year ended December 31, 2022. Refer to note 6 [27] for the consolidated financial statements for the year ended December 31, 2022 for the relevant information.

(29) Non-cash transactions of investments and financing activities

I) Only part of the received cash of investments activities:

Acquisition the subsidiaries

	Six Months Ended June 30			
		2023	2022	
equisition cost from subsidiaries	\$	3,161,999	-	
ection: Accounts payable for the end of the year		(316,200)	-	
ash and equivalent cash listed on the subsidiaries from				
quisition date		(1,380,961)	-	
et cash inflow from mergeing the subsidiaries in the				
priod	\$	I,464,838	-	
ection: Accounts payable for the end of the year ash and equivalent cash listed on the subsidiaries from quisition date et cash inflow from mergeing the subsidiaries in the		(316,200) (1,380,961)	- - -	

2) The reconciliation of liabilities from financing activities was as follows:

				Changes in		
				Effect from subsidiaries the	Assessment	
	Janu	uary I, 2023	Cash flows	first time	adjustment	June 30, 2023
Short-term						
borrowings	\$	1,051,460	(401,460)	-	-	650,000
Long-term						
borrowings (including						
loans due within one						
year)		1,265,488	3,120,561	-	(7,482)	4,378,567
Guarantee deposit						
received		12,923	(2,981)	367	-	10,309
Lease liabilities						
(including related						
parties)		523,908	(53,377)	11,154	-	484,685
Total liabilities from						
financing activities	\$	2,856,779	2,662,743	11,521	(7,482)	5,523,561

				Changes in non-cash			
	Ja	nuary I,		Amendment	Assessment		
		2022	Cash flows	lease	adjustment	June 30, 2022	
Short-term borrowings	\$	586,849	(108,529)	-	-	478,320	
Long-term borrowings (including loans due							
within one year)		1,306,694	(40,515)	-	221	I,266,400	
Guarantee deposit received		25,912	(5,785)	-	-	20,127	
Lease liabilities (including related parties)		152,033	(49,714)	1,170	-	103,489	
Total liabilities from financing activities	\$	2,071,488	(204,543)	1,170	221	I,868,336	

7. Related-party Transactions

(1) Name and relationship of related parties

Name of related parties	Relationship with the Company
Qisda Corporation (Qisda)	Parent company of the Combined Company
Visco Vision Inc. (Visco Vision)	Affiliated company of the Combined Compan
MLK Bioscience Co., Ltd	Affiliated company of the Company
Visco Technology Sdn. Bhd.(VVM)	Subsidiary of Visco Vision
Other related parties:	
BenQ foundation	The actual related parties of Qisda
Darfon Electronics Corp. (Darfon)	Affiliated company of Qisda
	The corporate shareholder of Qisda
AU Optronics Corp. (AU)	accounting for using the equity method
AU Optronics (Suzhou) Corp. (AUS)	Subsidiary of AUO
AU Optronics (Kunshan) Corp.	Subsidiary of AUO
AU Optronics (Xiamen) Corp. (AUX)	Subsidiary of AUO
Darwin Precisions Industry (Xiamen) Corp.	Subsidiary of AUO
Darwin Precisions Industry Corp.	Subsidiary of AUO
Fuxun Optoelectronics Industry (Suzhou) Co., Ltd	Subsidiary of AUO
AUO Display Plus Corp.	Subsidiary of AUO
Suzhou BenQMedical Hospital (SMH)	Subsidiary of Qisda
Aon Medical Equipment Trading (Suzhou)	Subsidiary of Qisda
Lily-Medical Corp.	Subsidiary of Qisda
Darly Venture Inc.	Subsidiary of Qisda
Darly Consulting Corporation	Subsidiary of Qisda
BenQ Asia Pacific Corp.	Subsidiary of Qisda
BenQ Asia Pacific Singapore Co., Ltd.	Subsidiary of Qisda
BenQ Asia Pacific Thailand Co., Ltd.	Subsidiary of Qisda
ACE Energy Co,. Ltd (the origional name is BenQESCO	
Corp.)	Subsidiary of Qisda
Metaguru Corporation (the origional name is BenQ	
Guru Corporation)	Subsidiary of Qisda
BenQ Corp.	Subsidiary of Qisda
BenQ Technology (Shanghai) Co., Ltd.	Subsidiary of Qisda
Partner Tech Corp.	Subsidiary of Qisda
BenQ Medical Technology Corp.	Subsidiary of Qisda
BenQ AB DentCare Corporation	Subsidiary of Qisda
BenQ HEALTHCARE CORPORATION	Subsidiary of Qisda
BenQ Intelligent Technology (Shanghi) Co., Ltd	
Suzhou Qisda Optoelectronics Co., Ltd.	Subsidiary of Qisda
Metaage Corporation (The origional name is Sysage	
Technology Co., Ltd)	Subsidiary of Qisda

Name of related parties	Relationship with the Combined Company
Ace Pillar Co., Ltd.	Subsidiary of Qisda
Data Image Corp.	Subsidiary of Qisda
Aewin Technologies Co., Ltd.	Subsidiary of Qisda
AdvancedTEK International Corp.	Subsidiary of Qisda
Global intelligence Network Co., Ltd.	Subsidiary of Qisda
Simula Technology Inc.	Subsidiary of Qisda
BenQ Medical Equipment (Shanghai) Co., Ltd.	Subsidiary of Qisda
Alpha Network Inc.	Subsidiary of Qisda
Epic Cloud information Intergation Corp.	Subsidiary of Qisda
Statinc Company	Subsidiary of Qisda
Action Star Technology Co., Ltd.	Subsidiary of Qisda
Standard Technology Corp.	Subsidiary of Qisda
CONCORD MEDICAL CO., LTD	Subsidiary of Qisda
EASTECH CO., LTD	Subsidiary of Qisda
Diva Laboratories Ltd.	Subsidiary of Qisda

(2) The Company's significant related party transactions

I) Operating income

	Г	hree Months En	ded June 30	Six Months Ended June 30		
	2023		2022	2023	2022	
Other related parties:						
AU	\$	947,468	866,505	1,780,512	1,937,936	
AUS		253,780	199,658	483,141	522,417	
AUX		234,650	253,025	426,683	423,002	
Others		8,670	4,373	12,546	11,438	
Affiliated of company - VVM		33,901	42,615	69,804	78,487	
Other affiliated companies		-	240	-	480	
	\$	1,478,469	1,366,416	2,772,686	2,973,760	

The transaction price sold to related parties is not significantly different from the general sales prices, except that there is no general action price to compare due to the different specifications of some commodities. The collection period is 60~120 days, which is not significantly different from ordinary transactions.

2) Purchases

	Three Months Ended June 30			Six Months Ended June 30		
	2023		2022	2023	2022	
Affiliated of company-Visco Vision	\$	76,937	90,280	1 40,463	179,557	

The purchase prices for the transactions of related parties were not comparable to the purchase prices for the third-party customers as the specifications of products were different. The purchase prices were under the purchase arrangement and conditions.

3) Property transaction

The aggregated prices of the Company acquired other assets of related parties were as follows:

Related-party			hree Months E	Ended June 30	Six Months Ended June		
categories	Account		2023	2022	2023	2022	
Parent of company	Intangible assets	\$	-	450	-	1,749	
Other related parties	Intangible assets		368	2,171	6,456	5,509	
	Real estate, plant and						
Other related parties	equipment		795	3,240	795	3,240	
		\$	1,163	5,86 I	7,341	10,498	

In January, 2022, the Combined Company sold the machinery equipment to Other related parties by \$320 thousand, derived the disposal of the loss of \$2,405 thousand, the related expenses had been received as of the end of June 30, 2022.

4) Lease

The Combined Company rent and pay for the plants and offices from AUO every month, which is referred to neighboring areas for the rental. In 2022, the Combined Company signed a new contract with AUO to rent the office from them, and recognized the same amount as right-of-use assets and lease liabilities was amounted to \$474,749 thousand. Interest expense for the three and six months ended June 30, 2023, and 2022, amounted to \$1,987 thousand, \$275 thousand, \$4,076 thousand and \$652 thousand. As of June 30, 2023, December 31, and June 30, 2022, the lease liabilities amounted to \$428,858 thousand, \$474,526 thousand, and \$47,150 thousand.

The Company rent its plants and offices to related parties. The aggregated rental income (are recorded under the operating revenue) was as follows:

	Thr	ee Months En	ded June 30	Six Months Ended June 30		
	2	023	2022	2023	2022	
Other related parties	\$	352	357	705	709	

5) Dividend

(1) As of June 30, 2023, December 31 and June 30 2022, the dividends of the related parties of the receivable (are recorded under the related parties of the other receivables) for the Combined Company, the details are as follows:

	June	e 30, 2023	December 31, 2022	June 30, 2023	
Affiliated of company	\$	51,336	-	39,335	

(2) As of June 30, 2023, December 31 and June 30 2022, the dividends of the related parties of the payable (are recorded under the dividends of payables) for the Combined Company, the details are as follows:

	June 30, 2023		December 31, 2022	June 30, 2022	
Parent of company	\$	87,319	-	65,489	
Other related parties		192,062	-	144,046	
	\$	279,381	-	209,535	

6) Donation

As of the three and six month ended June 30, 2023 and 2022, the Combined Company donated to BenQ foundation, amounted to \$2,500 thousand, \$3,000 thousand, \$2,500 thousand and \$3,000 thousand, respectively.

7) Accounts receivable – related parties

In summary, the Company's accounts receivable of related parties are detailed below:

Account Related-party categories		une 30, 2023	December 31, 2022	June 30, 2022
Accounts receivable - related				
parties, net	Others related parties- AUC	\$ 804,722	495,602	618,447
	Others related parties- AUS	85,129	155,639	143,612
	Other related parties- AUX	76,626	165,969	46,523
	Other related parties- other	9,622	4,406	5,187
	Affiliated company - VVM	30,222	31,231	36,481
	Other affiliated companies	-	299	504
	Subtotal	1,006,321	853,146	850,754
Other receivables – related parti	es Other related-parties	50	10	10
	Affiliated company - Visco			
	Vision	51,336	-	39,335
	Subtotal	51,386	10	39,345
	_	\$ 1,057,707	853,156	890,099

The Company entered factoring contracts with financial institutions to sell its accounts receivable from related parties without recourse. These contracts met the condition of financial asset derecognition, details of these contracts were as follows:

				June 30, 2	023		
					Amount		-
					transferred to		
					other		
			Amount of		accounts	Range of	
	F	actored	advance	Advance	receivable	interest	
Underwriter		amount	available	amount	(Note 6(5))	rate	Other important matters
Mega							
nternational Bank	\$	241,889		217,700	24,189	6.41%	Promissory note 150,000
	φ		-				
CTBC Bank		460,418	-	414,376	46,042	5.95%	None -
	\$	702,307	-	632,076	70,231		150,000
				December 3	1,2022		
					Amount		
					transferred to		
					other		
			Amount of		accoiunts	Range of	
	F	actored	advance	Advance	receivable	interest	
Underwriter		amount	available	amount	(Note 6(5))	rate	Other important matters
Mega							
nternational Bank	\$	512,167	_	460,950	51,217	5.44%	Promissory note 150,000
CTBC Bank	Ψ	361,931		325,738	36,193	5.10%	,
			-			5.10%	None -
	\$	874,098	-	786,688	87,410		150,000
				June 3	0, 2022		
					Amount		
					transferred other		
			Amount	.f	accoiunt	s Rango	a of

			Amount of		accoiunts	Range of	
	F	actored	advance	Advance	receivable	interest	
Underwriter	ā	amount	available	amount	(Note 6(5))	rate	Other important matters
Mega International							
Bank	\$	330,222	-	297,200	33,022	3.18%	Promissory note 150,000
CTBC Bank		445,800	-	401,220	44,580	2.55%	None -
	\$	776,022	-	698,420	77,602		150,000

8) Accounts payable - related parties

In summary, the Company's accounts payable – related parties are detailed below:

	Categories of the				
Account	related parties	June	e 30, 2023	December 31, 2022	June 30, 2022
Accounts payable -					
related parties	Affiliated companies	\$	51,470	34,905	73,604
Other payables -					
related parties	Other related parties		18,083	19,987	19,575
	Parent company		5,473	100	4,341
	Affiliated companies		96	H	-
	Subtotal		23,652	20,098	23,916
		\$	75,122	55,003	97,520

(3) Compensation of major managerial personnel

	Three Months Ended June 30			Six Months Ended June 30		
	2023		2022	2023	2022	
Short-term employee benefits						
and compensation	\$	14,521	16,626	25,590	32,800	
Retirement benefits		81	81	162	162	
	\$	14,602	16,707	25,752	32,962	

8. Pledged assets

The details of the carrying value of pledged assets by the Combined Company were as follows:

	Purpose of					
Asset name	pledge	June 30, 2023		December 31, 2022	June 30, 2022	
	Short-term and					
	Long-term					
Land, buildings and structures	borrowings	\$	1,538,298	617,584	623,593	
Other financial assets - current	Customs deposits		8,133	10,464	-	
Other financial assets - current -	Project guarantee					
deposit certificatied	deposit		4,608	4,608	-	
Other financial assets - non-current	-					
deposit certificatied	Performance bond		9,252	-	-	
		\$	1,560,291	632,656	623,593	

9. Material contingent liabilities and unrecognized contractual commitments

Significant unrecognized contract commitments:

	Jun	ne 30, 2023	December 31, 2022	June 30, 2022
Unused letters of credit issued	\$	1,269,128	1,552,960	1,453,649
Signed and unpaid major				
engineering and equiptment				
payments		1,963,782	2,181,554	1,100,813

10. Significant Loss from disaster: None

II. Significant subsequent events: None

12. Others

(1) The function of employee benefits, depreciation, and amortization expenses are summarized as follows

Function	Three Mon	ths Ended Jur	ne 30, 2023	Three Months Ended June 30, 2022			
Nature	Operating	Operating		Operating	Operating		
Nature	costs	expenses	Total	costs	expenses	Total	
Employee benefits							
expenses:							
Salaries expenses	404,375	244,087	648,462	400,143	234,457	634,600	
Labor insurance							
and national health							
insurance	32,266	16,710	48,976	29,482	14,641	44,123	
Pension expenses	15,928	10,770	26,698	14,251	9,575	23,826	
Other employee							
benefits expenxes	20,108	8,618	28,726	21,863	8,776	30,639	
Depreciation	185,736	36,976	222,712	121,409	28,044	149,453	
Amortization	5,378	8,703	14,081	4,286	10,838	15,124	

Function	Six Montl	hs Ended June	30, 2023	Six Montl	ns Ended June	30, 2022
	Operating	Operating		Operating	Operating	
Nature	costs	expenses	Total	costs	expenses	Total
Employee benefits						
expenses:						
Salaries expenses	766,421	454,353	1,220,774	790,762	445,279	1,236,041
Labor insurance						
and national health						
insurance	66,708	35,455	102,163	62,036	31,481	93,517
Pension expenses	31,545	21,459	53,004	27,948	18,557	46,505
Other employee						
benefits expenxes	41,199	17,299	58,498	41,966	16,405	58,371
Depreciation	372,097	72,786	444,883	245,404	52,948	298,352
Amortization	7,664	16,618	24,282	8,688	21,285	29,973

(2) The Company's operations are not materially influenced by seasonality or periodicity

13. Additional disclosures

(1) Information on significant transactions:

For the six months ended June 30, 2022, the Company should disclose relevant information on significant transactions in accordance with preparation of financial reports:

I) Financing provided to other parties:

```
(Unit: NT$ thousand)
```

												Colla	teral			
				Highest												
			Whethe	endorsement										Limit on		
			r he/she	or guarantee							Allowance			loans		
			is	amount for	Balance at	Actual		Nature of			forallowan			granted to	Fund Ioan	
Lending	Lending	Contact	related	current	the end of	amount	Interest	financing	Tranction	Reason for	ce for loss	Nam	Valu	a single	and total	
company	subject	accounts	party	period	year	expenditure	rate range	(Note 2)	amount	financing	amount	е	е	party	limit	Note
		Other														
		receivables-														
BMS	BenQ Materials	related		1,180,045	1,136,771	884,965				Operating						
(Notel)	(Wuhu) Corp.	patries	Yes	(RMB 265,000)	(RMB 265,000)	(RMB 206,300)	1.30%	2	-	turnover	-		-	1,857,561	1,857,561	(Note I)
	BenQ Materials	Other														
	Medical	receivables-														
BMS	(Suzhou) Co.,	related		444,170	428,970	288,697				Operating						
(Note I)	Ltd.	patries	Yes	(RMB 10,000)	(RMB 10,000)	(RMB 67,300)	1.30%	2	-	turnover	-		-	1,857,561	1,857,561	(Note I)
	Web-	Other														
	vved- Pro(Vietnam	receivables-		860,000	860,000	456,536	1.00%	2						610,089	1,220,179	
	,	related		860,000	860,000	456,536	1.00%	2	-	Operating	-		-	610,067	1,220,179	
	Co., Ltd)	patries	Yes							turnover						(Note 2)
	BenQ Materials	Other														
DTD	Medical	receivables-					1.30%	2						21.005	21.005	
DTB	(Suzhou) Co.,	related		22,209	21,449	18,017	1.30%	2	-	Operating	-		-	31,895	31,895	
	Ltd.	patries	Yes	(RMB 5,000)	(RMB 5,000)	(RMB 4,200)				turnover						(Note 3)

(Note I): The total amount of the BMS fund loan and the 100%-owned subsidiary of the ultimate parent company and the fund loan and limit for individual objects are the net value of the latest financial statement of BMS with the certificate of accountant.

(Note 2): The maximum amount of Web-Pro capital loan is limited to 40% of the net value of the latest financial statement certified by an accountant. The individual loan amount shall not exceed 20% of the net value of the latest financial statement certified by an accountant.

(Note 3): The total amount of funds loaned by DTB to subsidiaries that are 100% owned by the ultimate parent company and the limit of funds loaned to individual objects are the net value of DTB's most recent financial statements certified by accountants.

(Note 4): Those who have business dealings with the nature of capital loans are 1, and 2 for those who require short-term financing.

(Note 5): It has already been written off during compilation of the Consolidated Financial Statements.

- 2) Endorsements and guarantees provided for others: None.
- 3) Holding of marketable securities at the end of the period (excluding investment in subsidiaries, affiliated and joint equity):

					Ending	g Balance		
Name of company held	Type and name of marketable securities	Relationship with the securities issuer	Listed accounts	Shares	Book amount	Ownership (%)	Fair Value	Note
BenQ	Shares of Biodenta		Financial assets at fair value					
	Corporation	-	through the profit and loss	225	(Note)	2.50%	-	-
BenQ	Shares of Lagis		Financial assets at fair value					
	Corporation	-	through other comprhensive				64,713	-
	Corporation		income	I ,680	64,713	5.25%		
BenQ	Shares of Summed		Financial assets at fair value					
	Corporation	-	through other comprhensive				1,972	-
	Corporation		income	300	1,972	2.73%		
BenQ	Shares of Cuumed		Financial assets at fair value					
	Catheter Medical Co., Ltd	-	through other comprhensive				94,078	-
			income	3,429	94,078	8.76%		

(Note): It was all recognized as impairment losses.

4) Acquisition or sale of the same security with the accumulated cost reaching NT\$300 million or more than 20% of the paid-in capital or more: None.

					The beginningof the period		Acquisition			Sa	le		The end of the period (note)	
Acquisition and sale from	Type and name of marketable	Listed	Transa	Relatio						Selling	Cost on carryin g amoun	Profit and loss on disposa		
company	securities	accounts	ctor	nship	Share	Amount	Share	Amount	Share	price	t	I	Share	Amount
The company	Wep-Pro	Investment under the	Original sharehol	None	-	-	35,700	3,161,999	-	-	-	-	35,700	2,862,823
		equity	der for											
		method	Web- Pro											

- 5) Acquisition of the real estate reaching NT\$300 million or more than 20% of paid-in capital or more: None.
- 6) Disposal of the real estate reaching NT\$300 million or more than 20% of paid-in capital or more: None.
- 7) Those who purchase or sell with a related party in the amount of NT\$100 million or more than 20% of the paid-in capital.

				Tranction detail				nces in ion terms o third-party actions		cconuts (payable)	
		Relationshi p with the			Ratio to total					Ratio to total notes or accounts	
Purchaser (seller)	Counter party	counter party	Purchases	Amount	purchase (sell)	Credit	Unit price	Credit	Balance		Commentar
(seller)	party	Other related	(sales)	Amount	(sell)	period	Unit price	period	Balance	(payable)	У
BenQ	AUO	parties	Sales	1,780,512	25%	OA90	(Note I)	(Note 3)	804,722	26%	-
BenQ	AUS	Other related parties	Sales	483,141	7%	OA90			85,129	3%	-
BenQ	AUX	Other related parties	Sales	426,683	6%	OA90	"	"	76,626	2%	-
BenQ	вмм	Parent company and subsidiary	Sales	172,062	2%	OA180	"	"	95,084	3%	(Note 4)
		Parent company and									
BenQ	Sigma-Medical	subsidiary	Sales	129,210	2%	OA180	"	"	15,196	0%	(Note 4)
		Parent company and									
BenQ	BMS	subsidiary	Purchases	(483,672)	10%	OA180	(Note 2)		(252,111)	8%	(Note 4)
BenQ	Visco Vision	Joint venture	Purchases	(140,463)	3%	OA60	"	"	(51,470)	2%	-

(Note I): The sales prices for the transactions of related parties were not comparable to the sales prices for third-party customers as the specifications of products were different. For the other transactions, there were no significant differences between the sales prices for related parties and those for third-party customers.

(Note 2): The purchase prices for the transactions of related parties were not comparable to the purchase prices for third-party customers as the specifications of products were different. For the other transactions, there were no significant differences between the purchase prices for related parties and those for third-party customers.

- (Note 3): These transactions were no significant differences between related parties and those for third-party customers.
- (Note 4): The transactions have been eliminated when preparing the consolidated financial statements.

(Note 5): Due to the amounts of transactions of purchases and sales between the Company and related parties is insignificant, combined disclosure is adopted.

8) Receivables from related parties reaching NT\$100 million or more than 20% of paid-in capital or more:

Company		counter	Balance dues from related	Turnover	Overdue receivables		Amount collected subsequent to the balance	Allowance for doubtful
name	Counter party	party	parties	rate (note I)	Amount	Action taken	sheet date	accounts
		Other related						
BenQ	AUO	parties	804,722	3.47	-	-	-	-
		Parent						
		company and						
BMS (Note 2)	BenQ	subsidiary	252,111	1.96	-	-	41,649	-

(Note I): The turnover rate is calculated by adding back of the amount of account receivables sold to financial institutions.

(Note 2:) The transactions have been eliminated when preparing the consolidated financial statements.

- 9) Trading in derivative instruments: The transactions information of trading in derivative instruments by the Company, please refer to Note 6 [2] for the consolidated financial statements for the details.
- 10) Business relationships and significant intercompany transactions among parent and subsidiaries:

					Trai	nsaction (Note 3)	
							Percentage of
							consolidated total
	Company	Counter	Relationship				operating revenues or
No. (Note I)	name	party	(Note 2)	Account	Amount	Transaction term	total assets (Note 4)
1	BMS	BenQ	2	Accounts receivable	252,111	OA180	I.25%
1	BMS	BenQ	2	Processing income	483,672	OA180	5.56%
2	BenQ	вмм	I	Sales	I 72,062	OA180	I.98%
3	BenQ	Sigma-Medical	I	Sales	129,210	OA180	I.48%

(Note I): The number is filled in as follows:

(I) Number 0 represents the parent.

(2) Subsidiaries are numbered in order from number 1.

(Note 2): The transaction relationships with the counterparties are as follows:

- (1) The parent to the subsidiary.
- (2) The subsidiary to the parent.
- (3) The subsidiary to another subsidiary.

(Note 3): The significant inter-company transactions, only the transactions of sales and accounts receivable have been disclosed, over consolidated operating and assets up to 1%, due to the amounts of transactions of purchases and accounts payable between the Company and related parties are insignificant, combined disclosure is adopted.

(Note 4): The percentage is divided by consolidated operating revenues or consolidated total assets.

(Note 5): The transactions have been eliminated when preparing the consolidated financial statements.

(2) Information on investees:

The information of investee companies for the six months ended June 30, 2023 (excluding investees in China):

				Initial invest	ment amount	Shares h	eld as of June	30, 2022	Net profit	Investment	
			Main	Balance as	Balance as	0.10.05.1			(loss) of the		
			business	of June 30,	of Dec. 31	Number of	Ownership(Carrying	investee for		
Investor	Investee	Location	activities	2023	2022	shares	%)	amount	the current	. ,	Comentary
			Investment			51141 00		uniounio			
BenQ	BMLB	Malaysia	holding	499,790	1,141,340	14,082	100.00%	1,666,614	(7,052)	(7,052)	(Note I)
			Manufacture		, ,	,		,,-	(,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		(/
			and sales of								
			medical								
BenQ	Sigma-Medical	Taiwan	equipment	231,727	231,727	2,000	100.00%	74,035	22,715	22,755	(Note I)
			Manufacture								
			and sales of								
BenQ	Visco Vision	Taiwan	contact lenses	168,771	168,771	9,334	14.82%	422,870	95,938	17,428	
			R&D,								
			manufacture								
			and sales of								
			medical								
BenQ	Cenefom	Taiwan	equipment	272,968	272,968	11,646	50.98%	222,592	(3,639)	(3,302)	(Note I)
			R&D,								
			manufacture								
			and sales of								
BenQ	Consist	Taiwan	medical	43,316	43,316	3,767	70.00%	42,775	1,036	(36)	
BellQ	Genejet	Talwall	equipment R&D,	43,316	45,516	3,767	70.00%	42,775	1,036	(36)	(Note I)
			manufacture								
			and sales of								
			hygienic								
			medical								
BenQ	Web-Pro	Taiwan	production	3,161,999	-	35,700	51.00%	2,862,823	122,923	55,485	(Note I)
			R&D, and								
			sales of								
			medical								
BenQ	Bution	Taiwan	equipment	6,000	6,000	217	20.00%	4,224	(644)	(135)	
			Sales of								
			medical								
BenQ	Coatmed	Taiwan	equipment	5,980	5,980	598	9.98%	4,587	(3,602)	(387)	
		_	Investment								
Web-Pro	WPSG	Singapore	holding	450,714	-	15,500	100.00%	362,595	(31,117)	-	(Note I)
			Manufacture								
			and sales of								
			hygienic								
WPSG	WPVN	Vientam	medical production	460,950			100.00%	346,717	(29,551)		(Note I)
11130		vientain	Production	700,730	-	-	100.00%	540,717	(27,551)	-	

(Note 1): The transactions have been eliminated when preparing the consolidated financial statements

(3) Information on investments in China:

I) Relevant information on investments in China:

					Amount re	mitted from						
					Taiwan o	or amount						
					remitted ba	ck to Taiwan						
					for the cur	rent period						
				Accumulate			Accumulate			Investment		
				d amount of			d amount of			income		Investment
				remittance			remittance	Net income	Ownership	(loss)	Carrying	profits
				from			from	ofinvestee	held by	recognized	amount of	repatriated
Investee in	Main		Investment	Taiwan as of	Remitted to	Remitted	Taiwan as of	for the	BenQ	for the	investments	by the end of
Mainland	business	Paid-in	method	January I,	Mainland	back to	June 30,	current	(direct or	current	as of June	the current
China	activities	capital	(Note I)	2023	China	Taiwan	2023	period	indirect)	period	30, 2023	period
BenQ Material	Processing of											
(Suzhou)	functional film	248,800		901,900		641,550	248,800			33,190	1,857,561	
Corp. (BMS)	products	(USD 8,000)	(3)	(USD 29,000)	-	(USD 21,000)	(USD 8,000)	33,190	100.00%	(Note 2)	(Note 4)	-
	Provision of											
	services and											
Daxon	sales of related											
	products such											
(Suzhou) Co.,	as medical	47,187								6,215	31,895	
Ltd. (DTB)	equipment	(RMB 1,000)	(2)	-	-	-	-	6,215	100.00%	(Note 2)	(Note 4)	-
	Manufacture											
	and sales of											
BenQ	film sheet and											
Materials	cosmetic-						171,588					
· / ·	related	343,176		171,588			(RMB 40,000)			(19,357)	(200,040)	
. ,	products	(RMB 80,000)	(3)	(RMB 40,000)	-	-	(Note 3)	(20,214)	100.00%	(Note 2)	(Note 4)	-
BenQ												
	Manufacture											
	and sales of											
· , , ,	medical	64,346								(27,861)	17,727	
· ,	equipment	(RMB 15,000)	(2)	-	-	-	-	(27,861)	100.00%	(Note 2)	(Note 4)	-
Suzhou Sigma												
Medical												
,	Sales of											
``	medical	22,454		22,454			22,454				1,065	
Sigma)	equipment	(USD 722)	(1)	(USD 722)	-	-	(USD 722)	I	100.00%	(Note 2)	(Note 4)	-

(Note 1): Investment methods are classified into the following three categories:

(1) Directly invest in a company in China.

(2) The reinvestments in China were from the earnings of BMLB.

(3) Indirect investment in China is through a holding company established in a third country.

(Note 2): Investment income or loss was recognized based on the reviewed financial

statements issued by the auditors of the parent in Taiwan.

(Note 3): The amounts of BMLB reinvestments RMB10,950 thousand were excluded.

(Note 4): The transactions have been eliminated when preparing the consolidated financial statemen

2) Limits on investments in Mainland China:

(Unit: NT\$ thousand)

	Accumulated amount of		
	remittance from Taiwan to	Investment amounts	Upper limit on investment
	Mainland China as of June	•	by Investment Commission,
Company name	30, 2023	Commission, MOEA	ΜΟΕΑ
	420,388	531,706	
BenQ	(USD 8,000 and RMB 40,000)	(USD 8,000 and RMB 65,950)	(Note)
Sigma-Medical	22,454 (USD 722)	22,454 (USD 722)	80,000

It is converted according to the exchange rate of USD to NTD of 31.10 and RMB to NTD of 4.2897 at the end of the period.

3) Significant transactions with investee companies in China:

The direct or indirect transactions in China have been eliminated when preparing the consolidated financial statements for the six months ended June 30, 2023, please refer to "Information on significant transactions" for the details.

(4) Major shareholders information

Shares		
Name	Shareholding	Shareholding ratio
BenQ Corp.	80,847,763	25.21%
Qisda Crop.	43,659,294	13.61%

(Note): This table is calculated by Taiwan Depository & Clearing Corporation (TDCC) on the last business day of every season. To compute the shareholding companies' 5% of total of the ordinary shares and special shares of non-physical securities (including treasury shares). As for the company's financial reporting, it has written down that the share and the company's completed non-physical securities' shareholding might be discrepancy due to its different ways of factorization.

14. Segment information

The reportable business segment of the Combined Company includes the film sheet and medical segment. The film sheet segment is mainly engaged in the sales, manufacturing and research, and development of various electronic chemical membrane products.

The accounting policies of the operating segment, except for operating expenses and non-operating income (expenses) that cannot be directly attributable to each operating department, it is calculated based on the proportion of the revenue (or headcount) of each operating segment to the total revenue (or headcount). The income tax expense is not apportioned but directly included outside the film sheet segment, and the rest is the same as the summary of the important accounting policies described in Note 4. The profit and loss of the operating segment is measured by the after-tax profit and loss and used as the basis for evaluating performance. The Combined Company deems the inter-unit sales and transfer as transaction with third parties.

The Company's operating segment information and reconciliation are as follows:

		Three Months Ended June 30, 2023										
	Adjustments and											
	Film	sheet segment	Medical segment	Eliminations		Total						
External revenue	\$	3,403,457	1,231,589	-		4,635,046						
Intra-segment revenue		-	-	-		-						
Total revenue	\$	3,403,457	1,231,589	-		4,635,046						
Net profit after tax	\$	44,054	137,034	-	\$	181,088						

	Three Months Ended June 30, 2022						
	Film sheet segment		Medical segment	Eliminations	Total		
External revenue	\$	3,595,165	516,515	-	4,111,680		
Intra-segment revenue		-	-	-	-		
Total revenue	\$	3,595,165	516,515	-	4,111,680		
Net profit (loss) after tax	\$	214,036	45,480	-	259,516		
	-						

	Six Months Ended June 30, 2023						
	Adjustments and						
	Film sheet segment		Medical segment	Eliminations	Total		
External revenue	\$	6,440,476	2,261,514	-	8,701,990		
Intra-segment revenue		-	-	-	-		
Total revenue	\$	6,440,476	2,261,514	-	8,701,990		
Net profit after tax	\$	40,564	203,237	-	243,801		

Six Months Ended June 30, 2022						
Adjustments and						
t Eliminations	Total					
- 198	8,275,740					
-	-					
	8,275,740					
565 -	549,899					
,	Adjustments and					

The Company did not present the measured amount of total assets and total liabilities from segments to the Company's chief operating decision making.